AudioEye (AEYE) 10-K 2 Apr 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Apr. 02, 2018	Jun. 30, 2017
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Entity Registrant Name	AUDIOEYE INC
Entity Central Index Key	1,362,190
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 10,323,110
Trading Symbol	AEYE
Entity Common Stock, Shares Outstanding		161,664,077

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash	$ 1,960,430	$ 1,409,418
Accounts receivable	105,817	44,645
Marketable securities, held in related party	750	1,200
Prepaid expenses and other current assets	67,406	19,560
Total current assets	2,134,403	1,474,823
Property and equipment, net	34,994	0
Intangible assets, net	2,164,463	2,313,249
Goodwill	700,528	700,528
Total assets	5,034,388	4,488,600
Current liabilities:
Accounts payable and accrued expenses	82,628	245,677
Notes and loans payable, current	0	23,800
Related party payables	23,535	32,118
Derivative liabilities	2,984,010	3,478,626
Deferred rent	9,402	207
Deferred revenue	1,233,754	386,485
Total current liabilities	4,333,329	4,166,913
Long term liabilities:
Deferred rent	5,048	14,450
Total liabilities	4,338,377	4,181,363
Stockholders' equity:
Preferred stock, $0.00001 par value, 10,000,000 shares authorized, 110,000 and 160,000 shares issued and outstanding as of December 31, 2017 and 2016, respectively	1	2
Common stock, $0.00001 par value, 250,000,000 shares authorized, 161,664,077 and 111,512,001 shares issued and outstanding as of December 31, 2017 and 2016, respectively	1,617	1,115
Additional paid in capital	40,120,293	34,124,181
Accumulated deficit	(39,425,900)	(33,818,061)
Total stockholders' equity	696,011	307,237
Total liabilities and stockholders' equity	$ 5,034,388	$ 4,488,600

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Preferred Stock, Par or Stated Value Per Share	$ 0.00001	$ 0.00001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	110,000	160,000
Preferred Stock, Shares Outstanding	110,000	160,000
Common Stock, Par or Stated Value Per Share	$ 0.00001	$ 0.00001
Common Stock, Shares Authorized	250,000,000	250,000,000
Common Stock, Shares, Issued	161,664,077	111,512,001
Common Stock, Shares, Outstanding	161,664,077	111,512,001

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenues	$ 2,739,439	$ 994,265
Cost of revenue	1,384,145	1,226,321
Gross profit (loss)	1,355,294	(232,056)
Operating expenses:
Selling and marketing	1,421,127	713,972
Research and development	181,303	343,712
General and administrative	3,732,749	2,568,227
Impairment of related party non-marketable securities	0	50,000
Amortization and depreciation	538,761	570,247
Total operating expenses	5,873,940	4,246,158
Operating loss	(4,518,646)	(4,478,214)
Other income (expense):
Unrealized loss on derivative liabilities	(155,027)	(2,758,488)
Unrealized loss on marketable securities	(450)	(2,400)
Loss on settlement of debt	(15,724)	(1,664,281)
Other income	0	750
Interest expense, net	(917,992)	(675,997)
Total other income (expense)	(1,089,193)	(5,100,416)
Net loss	(5,607,839)	(9,578,630)
Dividend on Series A Convertible preferred stock	(75,206)	(80,000)
Net loss available to common stockholders	$ (5,683,045)	$ (9,658,630)
Net loss per common share-basic and diluted	$ (0.05)	$ (0.1)
Weighted average common shares outstanding-basic and diluted	117,335,917	98,905,556

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)	Total	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Balance at Dec. 31, 2015	$ 2,531,626	$ 817	$ 2	$ 26,770,238	$ (24,239,431)
Balance (in shares) at Dec. 31, 2015		81,717,154	175,000
Common stock issued upon conversion of preferred stock	0	$ 9	$ 0	(9)	0
Common stock issued upon conversion of preferred stock (in shares)		900,525	(15,000)
Common stock issued for services	63,292	$ 5	$ 0	63,287	0
Common stock issued for services (in shares)		416,664	0
Common stock issued in settlement of convertible notes and accrued interest	1,078,123	$ 128	$ 0	1,077,995	0
Common stock issued in settlement of convertible notes and accrued interest (in shares)		12,834,800	0
Common stock issued for cash, net of placement costs of $60,918	2,129,082	$ 156	$ 0	2,128,926	0
Common stock issued for cash, net of placement costs of $60,918 (in shares)		15,642,858	0
Common stock issued in settlement of convertible notes and accrued interest	3,205,959	$ 0	$ 0	3,205,959	0
Reclassify fair value of liability warrants issued in connection with sale of common stock	(280,777)	0	0	(280,777)	0
Restricted stock units issued in payment of accrued compensation	72,917	0	0	72,917	0
Beneficial conversion feature and warrants issued with convertible notes	0
Warrants and Options issued for services	1,085,645	0	0	1,085,645	0
Net loss	(9,578,630)	0	0	0	(9,578,630)
Balance at Dec. 31, 2016	307,237	$ 1,115	$ 2	34,124,181	(33,818,061)
Balance (in shares) at Dec. 31, 2016		111,512,001	160,000
Common stock and warrants sold for cash	1,550,000	$ 110	$ 0	1,549,890	0
Common stock and warrants sold for cash (in shares)		11,071,429	0
Common stock issued upon conversion of preferred stock	0	$ 32	$ (1)	(31)	0
Common stock issued upon conversion of preferred stock (in shares)		3,204,027	(50,000)
Common stock issued for services	25,001	$ 2	$ 0	24,999	0
Common stock issued for services (in shares)		166,672	0
Common stock issued in exchange for exercise of warrants on a cashless basis	0	$ 199	$ 0	(199)	0
Common stock issued in exchange for exercise of warrants on a cashless basis (in shares)		19,832,930	0
Common stock issued in exchange for exercise of warrants at $0.07 per share	210,000	$ 30	$ 0	209,970	0
Common stock issued in exchange for exercise of warrants at $0.07 per share (in shares)		3,000,000	0
Common stock issued in settlement of convertible notes and accrued interest	$ 865,336	$ 129	$ 0	865,207	0
Common stock issued in settlement of convertible notes and accrued interest (in shares)	2,198,926	12,877,018	0
Loss on settlement of convertible note payable	$ 15,724	$ 0	$ 0	15,724	0
Reclassify fair value of liability warrants issued in connection with sale of common stock	(6,062)	0	0	(6,062)	0
Reclassify fair value of liability warrants exercised	758,911	0	0	758,911	0
Restricted stock units, warrants and options issued for services	1,750,620	0	0	1,750,620	0
Restricted stock units issued in payment of accrued compensation	14,583	0	0	14,583	0
Beneficial conversion feature and warrants issued with convertible notes	812,500	0	0	812,500	0
Net loss	(5,607,839)	0	0	0	(5,607,839)
Balance at Dec. 31, 2017	$ 696,011	$ 1,617	$ 1	$ 40,120,293	$ (39,425,900)
Balance (in shares) at Dec. 31, 2017		161,664,077	110,000

CONSOLIDATED STATEMENT OF STOC6

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs		$ 60,918
Warrants exercise price per share	$ 0.07

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss)	$ (5,607,839)	$ (9,578,630)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	538,761	570,247
Amortization of debt discounts	862,500	600,301
Bad debt expense	3,202	0
Non cash interest expense associated with derivative warrants	39,944	0
Option, warrant, RSU and PSU expense	1,750,620	1,085,645
Stock issued or issuable for services	25,001	63,292
Change in fair value of liability warrants due to exercise price reduction	13,262	0
Unrealized loss on marketable securities	450	2,400
Impairment loss on non-marketable securities	0	50,000
Change in fair value of derivative liabilities	155,027	2,758,488
Loss on settlement of debt	15,724	1,664,281
Changes in operating assets and liabilities:
Accounts receivable	(64,374)	(21,904)
Other current assets	(47,846)	21,828
Accounts payable and accruals	(160,213)	151,858
Deferred rent	(207)	14,657
Deferred revenue	847,269	325,695
Related party payables	6,000	(48,439)
Net cash (used in) operating activities	(1,622,719)	(2,340,281)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment	(41,167)	0
Cash paid for intellectual property	0	(42,640)
Software development costs	(383,802)	0
Net cash (used in) investing activities	(424,969)	(42,640)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of common stock and warrants for cash	1,550,000	2,129,082
Issuance of convertible note payable	862,500	0
Proceeds from exercise of warrants	210,000	0
Repayments of notes payable	(23,800)	(24,000)
Net cash provided by financing activities	2,598,700	2,105,082
Net increase (decrease) in cash	551,012	(277,839)
Cash-beginning of period	1,409,418	1,687,257
Cash-end of period	1,960,430	1,409,418
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	0	0
Income taxes paid	0	0
Non cash investing and financing activities:
Reclassify fair value of liability warrants from equity to liability upon issuance	6,062	280,777
Reclassify fair value of liability warrant from liability to equity upon exercise	758,911	0
Debt discount from derivative feature warrants attached to note	50,000	0
Beneficial conversion feature and warrants issued with convertible notes	812,500	0
Common stock issued in settlement of convertible notes payable and accrued interest	865,336	1,078,123
Warrants issued in settlement of convertible notes and accrued interest	0	3,205,959
Restricted stock units issued in payment of accrued compensation	14,583	72,917
Common stock issued for cashless exercise of warrants	199	0
Common stock issued on conversion of preferred stock	$ 32	$ 9

ORGANIZATION

ORGANIZATION	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1 — ORGANIZATION AudioEye, Inc. (“we”. “our”, the “Company”) was incorporated on May 20, 2005 in the state of Delaware. On March 31, 2010, the Company was acquired by CMG Holdings Group, Inc., a Nevada corporation (“CMG”). Effective August 17, 2012, AudioEye Acquisition Corporation, a Nevada corporation (“AEAC”), acquired 80 The Company has developed patented, Internet content publication and distribution software that enables conversion of any media into accessible formats and allows for real time distribution to end users on any Internet connected device. The Company’s focus is to create more comprehensive access to Internet, print, broadcast and other media to all people regardless of their network connection, device, location, or disabilities. The Company is focused on developing innovations in the field of networked and device embedded audio technology. The Company owns a unique patent portfolio comprised of six issued patents in the United States, a notice of allowance from the U.S. Patent and Trademark Office for a seventh patent, and two U.S. patents pending with additional patents being drafted for filing with the U.S. Patent and Trademark Office and internationally. On August 17, 2012, AEAC acquired 80 1. CMG would retain 15 2. CMG would distribute to its stockholders, in the form of a dividend, 5 3. The Company entered into a Royalty Agreement with CMG to pay to CMG 10 4. The Company entered into a Services Agreement with CMG whereby CMG will receive a commission of not less than 7.5 10 On March 22, 2013, the Company and AEAC entered into the Merger Agreement. Pursuant to the Merger Agreement, each share of AEAC common stock issued and outstanding immediately prior to the Merger effective date would be converted into .94134 share of the Company’s common stock and the outstanding convertible debentures of AEAC (the “AEAC Debentures”) in the aggregate principal amount of $ 1,400,200 67,732 24,004,143 5,871,752 On November 12, 2013, the Company and CMG terminated the Royalty Agreement. On December 30, 2013, the Company completed the repurchase of 2,184,583 573,022 50,000

GOING CONCERN AND MANAGEMENT_S

GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS	12 Months Ended
	Dec. 31, 2017
Going Concern [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS As of December 31, 2017, the Company had cash of $ 1,960,430 2,198,926 785,084 1,622,719 In 2017, the Company sold shares of common stock and warrants for net proceeds, after commissions and other costs, of $ 1,550,000 The Company expects that cash used in operations will decrease significantly over the next several years as the Company executes its business plan. In the event that the Company is not able to fully achieve its plan, the Company may need to raise additional funds through equity or debt financing. If the Company is unsuccessful in raising additional financing, it will need to reduce costs and operations in the future. Accordingly, the accompanying financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The financial statements do not include any adjustment that might result from the outcome of this uncertainty.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 3 — SIGNIFICANT ACCOUNTING POLICIES This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Empire Technologies, LLC (“Empire”). All significant inter-company accounts and transactions have been eliminated. During the years ended December 31, 2017 and 2016, Empire had no activity. Empire had no assets or liabilities as of December 31, 2017 and December 31, 2016. The Company acquired 19.5 Revenue is recognized when all applicable recognition criteria have been met, which generally include (a) persuasive evidence of an existing arrangement; (b) fixed or determinable price; (c) delivery has occurred or service has been rendered; and (d) collectability of the sales price is reasonably assured. For software and technology development contracts the Company recognizes revenues on a percentage of completion method based upon several factors including but not limited to (a) estimate of total hours and milestones to complete; (b) total hours completed; (c) delivery of services rendered; (d) change in estimates; and (e) collectability of the contract. The Company had two major customers including their affiliates which generated approximately 28.4 18.0 10.4 The Company had two major customers including their affiliates which generated approximately 45.3 23.8 21.5 At December 31, 2017, the Company had five customers representing 18 14 14 13 10 69 29 18 47 Certain Software as a Service (SaaS) are prepared and invoiced on an annual basis. Any funds received for services not provided yet are held in deferred revenue, and are recorded as revenue when earned. In accordance with ASC 350-40, the Company capitalizes certain computer software and software development costs incurred in connection with developing or obtaining computer software for internal use when both the preliminary project stage is completed and it is probable that the software will be used as intended. Capitalized software costs include only (i) external direct costs of materials and services utilized in developing or obtaining computer software, (ii) compensation and related benefits for employees who are directly associated with the software project and (iii) any interest costs incurred while developing internal-use computer software. Capitalized software costs are included in intangible assets on our balance sheet and amortized on a straight-line basis when placed into service over the estimated useful lives of the software (see Note 6). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates. Research and technology expenses are expensed in the period costs are incurred. For the year ended December 31, 2017 and 2016, research and technology expenses totaled $ 181,303 343,712 The Company has a fiscal year ending on December 31. The Company considers cash in savings accounts to be cash equivalents. The Company considers any short-term, highly liquid investments with maturities of three months or less as cash and cash equivalents. The Company has elected the fair value option under ASC 825 for its marketable securities. Marketable securities are classified as available for sale and consist of common stock holdings of publicly traded companies. These securities are marked to market at the end of each reporting period based on the closing price of the security at each balance sheet date. Changes in fair value are recorded as unrealized gains or losses in the consolidated statement of operations in accordance with ASC 320. From time to time, the Company invests in the securities of other entities where there exists no active market for the securities held. Non-marketable securities are recorded at the cost of the investment. The Company establishes an allowance for bad debts through a review of several factors including historical collection experience, current aging status of the customer accounts, and financial condition of the Company’s customers. The Company does not generally require collateral for its accounts receivable. During the years ended December 31, 2017 and 2016, the Company incurred $ 3,202 0 0 Property and equipment are carried at the cost of acquisition or construction and depreciated over the estimated useful lives of the assets. Costs associated with repairs and maintenance are expensed as incurred. Costs associated with improvements which extend the life, increase the capacity or improve the efficiency of the Company’s property and equipment are capitalized and depreciated over the remaining life of the related asset. Gains and losses on dispositions of equipment are reflected in operations. Depreciation is provided using the straight-line method over the estimated useful lives of the assets, which are 5 7 Goodwill is carried at cost and is not amortized. The Company tests goodwill for impairment on an annual basis at the end of each fiscal year, relying on a number of factors including operating results, business plans, economic projections, anticipated future cash flows and marketplace data. Company management uses its judgment in assessing whether goodwill has become impaired between annual impairment tests according to specifications set forth in ASC 350. The Company completed an evaluation of goodwill at December 31, 2017 and 2016 and determined that there was no impairment. The fair value of the Company’s reporting unit is dependent upon the Company’s estimate of future cash flows and other factors. The Company’s estimates of future cash flows include assumptions concerning future operating performance and economic conditions and may differ from actual future cash flows. Estimated future cash flows are adjusted by an appropriate discount rate derived from the Company’s market capitalization plus a suitable control premium at date of the evaluation. The financial and credit market volatility directly impacts the Company’s fair value measurement through the Company’s weighted average cost of capital that the Company uses to determine its discount rate and through the Company’s stock price that the Company uses to determine its market capitalization. Therefore, changes in the stock price may also affect the amount of impairment recorded. The Company recognizes an acquired intangible asset apart from goodwill whenever the intangible asset arises from contractual or other legal rights, or when it can be separated or divided from the acquired entity and sold, transferred, licensed, rented or exchanged, either individually or in combination with a related contract, asset or liability. Such intangibles are amortized over their useful lives. Impairment losses are recognized if the carrying amount of an intangible asset subject to amortization is not recoverable from expected future cash flows and its carrying amount exceeds its fair value. The Company reviews its long-lived assets, including property and equipment, identifiable intangibles, and goodwill annually or whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of its long-lived assets, the Company evaluates the probability that future undiscounted net cash flows will be less than the carrying amount of the assets. The Company’s long-lived assets, including intangibles, are reviewed for impairment whenever events or changes in circumstances indicate that the historical-cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the asset by comparing the undiscounted future net cash flows expected to result from the asset to its carrying value. If the carrying value exceeds the undiscounted future net cash flows of the asset, an impairment loss is measured and recognized. An impairment loss is measured as the difference between the net book value and the fair value of the long-lived asset. Long-lived assets were evaluated for impairment and no impairment losses were incurred during the years ended December 31, 2017 and 2016, respectively. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the consolidated statements of operations, as if such amounts were paid in cash. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. These assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to reverse. The Company has net operating loss carryforwards available to reduce future taxable income. Future tax benefits for these net operating loss carryforwards are recognized to the extent that realization of these benefits is considered more likely than not. To the extent that the Company will not realize a future tax benefit, a valuation allowance is established. Basic earnings (loss) per share are computed by dividing net income, or loss, by the weighted average number of shares of common stock outstanding for the period. Diluted earnings (loss) per share and basic earnings (loss) per share are not included in the net loss per share computation until the Company has Net Income. Diluted loss per share including the dilutive effects of common stock equivalents on an “as if converted” basis would reduce the loss per share and thereby be antidilutive. 2017 2016 Preferred stock 7,108,996 9,122,007 Options to purchase common stock 25,095,557 25,731,207 Warrants to purchase common stock 47,997,335 63,433,041 Restricted stock units 3,908,471 1,252,620 Totals 84,110,359 99,538,875 The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedging relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2017 and 2016, the Company did not have any derivative instruments that were designated as hedges. On October 9, 2015, the Company issued convertible promissory notes representing $ 2,500,000 25,000,000 0.10 5 50,000 500,000 In addition, in 2016 and 2017, in connection with the sale of the Company’s common stock, the Company issued warrants exercisable for up to 1,792,000 0.25 5 In accordance with ASC 815, these outstanding warrants are deemed to be derivatives. The value of the derivative instrument will fluctuate with the price of the Company’s common stock and is recorded as a current liability on the Company’s Consolidated Balance Sheets. The change in the value of the liability is recorded as “unrealized gain (loss) on derivative liability” on the Consolidated Statements of Operations. This is a non-cash income (expense) item and is adjusted in the “operating activities” of the Consolidated Statements of Cash Flow. At December 31, 2017 and 2016, the derivative liability was stated at $ 2,984,010 3,478,626 155,027 The carrying amount of the Company’s financial instruments, consisting of cash equivalents, short-term investments, account and notes receivable, accounts and notes payable, short-term borrowings and certain other liabilities, approximate their fair value due to their relatively short maturities. The carrying amount of the Company’s long-term debt approximates fair value since the stated rate of interest approximates a market rate of interest. Fair value is an estimate of the exit price, representing the amount that would be received to upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants (i.e., the exit price at the measurement date). Fair value measurements are not adjusted for transaction cost. Fair value measurement under generally accepted accounting principles provides for use of a fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value into three levels: Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the Company. Level 3: Unobservable inputs reflect the assumptions that the Company develops based on available information about what market participants would use in valuing the asset or liability. An asset or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and liabilities and Level 3 assets and liabilities involve greater judgment than Level 1 and Level 2 assets or liabilities. In October and November 2015 and April 2017, the Company issued warrants with an exercise price of $ 0.10 0.10 The Company estimated the fair value of these derivative warrants at initial issuance and again at each balance sheet date. The changes in fair value are recognized in earnings in the Consolidated Statements of Operations under the caption “unrealized gain/(loss) – derivative liability” until such time as the derivative warrants are exercised or expire. The Company used the Black-Scholes Option Pricing model to estimate the fair value as of the dates of issuance, the price of the Company stock ranged $ 0.031 0.187 102 172 1.14 1.79 5 In 2016 and 2017, the Company issued warrants with an exercise price of $ 0.25 0.25 The Company estimated the fair value of these derivative warrants at initial issuance and again at each balance sheet date. The changes in fair value are recognized in earnings in the Consolidated Statements of Operations under the caption “unrealized gain/ (loss) – derivative liability” until such time as the derivative warrants are exercised or expire. The Company used the Black-Scholes Option Pricing model to estimate the fair value and as of the dates of issuance, the price of the Company stock ranged $ 0.152 0.195 169 178 1.22 1.87 5 280,777 6,062 On May 2, 2017, a warrant holder exercised a warrant to acquire 1,000,000 0.20 171 1.45 3.4 184,569 In October and November 2017, the Company offered, as an inducement to exercise, to reduce the exercise price of previously issued warrants from $0.10 per share to $ 0.07 0.139 0.1549 165 166 1.60 1.99 2.94 4.42 13,262 574,342 At December 31, 2017, the price of the Company stock was $ 0.1549 163.9 1.98 2.20 2.77 4.03 2,984,010 155,027 Fair Value Fair Value Hierarchy Assets Marketable securities, December 31, 2017 $ 750 Level 1 Marketable securities, December 31, 2016 $ 1,200 Level 1 Liabilities Derivative Liability , December 31, 2017 $ 2,984,010 Level 3 Derivative Liability , December 31, 2016 $ 3,478,626 Level 3 In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company anticipates early adoption of this pronouncement effective January 1, 2018. As such, the impact would the reclassification of the December 31, 2017 fair values of our warrant and derivative liabilities to equity. On January 1, 2018, the Company adopted ASU 2017-11 by electing the retrospective method to the outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the statement of financial position as of the beginning of the fiscal year. Accordingly, the Company reclassified the fair value of the reset provisions embedded in previously issued warrants with embedded anti-dilutive provisions from liability to equity (accumulated deficit) in aggregate of $ 2,984,010 In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. The updated guidance states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also provides for additional disclosures with respect to revenues and cash flows arising from contracts with customers. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017, and the Company will adopt the standard using the modified retrospective approach effective January 1, 2018. The most significant impact of the standard relates to capitalizing costs to acquire contracts, which have historically been expensed as incurred. As of December 31, 2017, the Company’s sales commission plans have included multiple payments, including initial payments in the period a customer contract is obtained and deferred payments over the life of the contract as future payments are collected from the customers. Under the standard, only the initial payment is subject to capitalization as the deferred payments require a substantive performance condition of the employee. These initial commission payments will be capitalized in the period a customer contract is obtained and will be amortized consistent with the transfer of the goods or services to the customer over the expected period of benefit. The expected period of benefit is the contract term, except when the commission payment is expected to provide economic benefit to the Company for a period longer than the contract term, such as for new customer or incremental sales where renewals are expected and renewal commissions are not commensurate with initial commissions. Such commissions will be amortized over the greater of contract term or technological obsolescence period when the underlying contracted products are technology-based, such as for the SaaS-based platforms, or the expected customer relationship period when the underlying contracted products are not technology-based, such as for patient experience survey products. The Company has determined that the adoption of ASU-2014-09 will not have a material impact on its consolidated financial statements. There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.

MARKETABLE AND NON-MARKETABLE S

MARKETABLE AND NON-MARKETABLE SECURITIES	12 Months Ended
	Dec. 31, 2017
Marketable Securities [Abstract]
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	NOTE 4 — MARKETABLE AND NON-MARKETABLE SECURITIES During 2014, the Company converted $ 60,000 600,000 60,000 24,000 2016 750 1,200 36,000 450 2,400 During 2014, the Company entered into a licensing transaction where it received 1,200,000 0 1,200,000 During 2014, the Company invested $ 50,000 97,500 50,000 60,000 97,500 At December 31, 2016, the Company management performed an evaluation of its investment in Cannonball Red for purposes of determining the implied fair value of the asset at December 31, 2016. The test indicated that the recorded book value of its investment exceeded its fair value for the year ended December 31, 2016. As a result, upon completion of the assessment, management recorded a non-cash impairment charge of $ 50,000 0

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 5 – PROPERTY AND EQUIPMENT Property and equipment as of December 31, 2017 and 2016 is summarized as follows: 2017 2016 Computer equipment $ 63,517 $ 25,478 Furniture and fixtures 3,128 - Total 66,645 25,478 Less accumulated depreciation (31,651) (25,478) Property and equipment, net $ 34,994 $ - Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful life of 3 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. The Company spent $41,167 in purchase of equipment during year ended December 31, 2017. Depreciation expense was $ 6,173 0

INTANGIBLE ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	NOTE 6 — INTANGIBLE ASSETS For the years ended December 31, 2017 and 2016, the Company invested in Software development costs in the amounts of $ 383,802 0 Patents, technology and other intangibles with contractual terms are generally amortized over their estimated useful lives of ten years. When certain events or changes in operating conditions occur, an impairment assessment is performed and lives of intangible assets with determinable lives may be adjusted. Software development costs are amortized over their estimated useful life of three years. Prior to any impairment adjustment, intangible assets consisted of the following: 2017 2016 Patents $ 3,697,709 $ 3,697,710 Capitalized software development 1,005,369 621,566 Accumulated amortization (2,538,615) (2,006,027) Intangible assets, net $ 2,164,463 $ 2,313,249 Amortization expense for patents totaled $ 379,158 373,398 153,430 196,849 Total amortization expense totaled $ 532,588 570,247

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 7 — RELATED PARTY TRANSACTIONS Dr. Carr Bettis, Executive Chairman and Chairman of Board of Directors As of December 31, 2017 and 2016, the Company owed Dr. Bettis $ 5,992 20,575 500 3,502 16,371 6,000 0 14,000 Sean Bradley, President, Chief Technology Officer, and Secretary As of December 31, 2017 and 2016, the Company owed Sean Bradley $ 3,543 David Moradi, 5% or more shareholder As of December 31, 2015 the Company owed David Moradi $ 70,000 4,280 44,912 Issuance of convertible notes payable In 2017, the Company issued an aggregate of $ 762,500 7,625,000 0.07 0.0672 Conversion of convertible notes payable On April 18, 2016, the Company issued 2,506,849 200,000 10,575 On April 18, 2016, the Company issued 1,251,142 100,000 5,096 On April 18, 2016, the Company issued an aggregate of 18,353,310 0.175 1,475,000 66,678 In 2017, the Company issued an aggregate of 11,346,726 762,500 Sales of common stock In 2016, the Company sold to CSB IV Holdings, a company under the control of Carr Bettis, an aggregate of 2,607,143 292,000 0.25 365,000 In 2016, the Company sold to Ernest Purcell, a member of the Company’s Board of Directors, 1,607,137 180,000 0.25 225,000 In 2016, the Company sold to Todd Bankofier, the Company’s Chief Executive Officer, 178,571 20,000 0.25 25,000 In 2016, the Company sold to Anthion Partners II, LLC, an entity under the control of David Moradi, 892,857 100,000 0.25 125,000 In 2017, the Company sold to Anthion Partners II, LLC, an entity under the control of David Moradi, 5,357,143 750,000 In 2017, the Company issued 750,000 52,500 In 2017, the Company issued 18,225,681 18,353,310 Other The Company holds 60,000 60,000 50,000 97,500 50,000 97,500 0 In summary, as of December 31, 2017 and 2016, the total balances of related party payable were $ 23,535 32,118

NOTES PAYABLE

NOTES PAYABLE	12 Months Ended
	Dec. 31, 2017
Notes Payable [Abstract]
Debt Disclosure [Text Block]	NOTE 8 — NOTES PAYABLE 0 23,800 Notes and loans payable 2017 2016 Short Term Maryland TEDCO $ - $ 23,800 Total $ - $ 23,800 Maryland TEDCO As of December 31, 2012, the Company had an outstanding loan to a third party in the amount of $ 74,900 25 74,900 The terms of the Release, among other things, terminated the Investment Agreement between the parties, and required the Company to issue a Promissory Note to the third-party in the combined amount of principal and accrued interest to date, for a total principal amount of $ 149,800 2,000 0 23,800 Convertible Secured Notes On April 11, 2017, the Company issued a convertible promissory note in the principal amount of $ 50,000 500,000 50 The Note bears interest at 10 If the Company sells equity securities in a single transaction or series of related transactions for cash of at least $ 1,000,000 60 The Warrant is exercisable at $ 0.10 5 The estimated fair value of the issued warrant of $ 89,944 50,000 39,944 50,000 On November 30, 2017, the Company issued 786,244 2,836 15,724 On October 11, 2017, the “Company entered into a Second Amendment to the Note and Warrant Purchase Agreement (the “Purchase Agreement Amendment”) and an Omnibus Amendment to Common Stock Warrants (the “Warrant Amendment”), which collectively amend that certain Note and Warrant Purchase Agreement dated as of October 9, 2015 (the “Original Agreement”) and the warrants previously issued thereunder (the “Warrants”) to, among other things; (i) for the period from the Closing Date until November 8, 2017 (the “Discount Period”), provide parties to the Original Agreement the option to purchase additional notes (in an amount of up to 50% of their respective original investment as provided in the Original Agreement) that will immediately convert to shares of common stock of the Company (“Common Stock”) at a price of $ 0.0672 warrants exercisable for shares of Common Stock at a price of $0.07 per share if exercised during the Discount Period or $0.10 per share if exercised during the term of the warrant following the Discount Period; (ii) provide for certain registration rights for shares of Common Stock issued pursuant to the Original Purchase Agreement, as amended, at any time after 30 days subsequent to the listing of the Common Stock on a national securities exchange; and (iii) amend the Warrants such that they are exercisable for shares of Common Stock at a price of $0.07 per share if exercised during the Discount Period or $0.10 per share if exercised during the term of the warrant following the Discount Period. The Company recognized a charge of $13,262 to current period interest for change in fair value due to the warrant modifications using the Black-Scholes pricing model 5 1.60 1.99 0 165.18 166.12 In November 2017, the Company issued convertible promissory notes in aggregate of $ 812,500 8,125,000 0.07 12,090,774 0.0672 750,000 52,500 In accordance with ASC 470-20, the Company recognized the value attributable to the warrants and the conversion feature in the aggregate amount of $812,500 to additional paid in capital and a discount against the November 2017 notes. The Company valued the warrants in accordance with ASC 470-20 using the Black-Scholes pricing model and the following assumptions: contractual terms of 5 1.83 2.01 0 165.45 166.12 812,500

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 9 — COMMITMENTS AND CONTINGENCIES Operating leases The Company’s principal executive offices are located at 5210 E. Williams Circle, Suite 750, Tucson, Arizona 85711, consisting of approximately 2,362 4,724 5,474 6,224 4,248 9,598 10,185 The Company also has offices in Atlanta, previously located at 1855 Piedmont Road, Suite 200, Marietta, Georgia leased for an aggregate of $ 2,763 3,937 3,831 1,500 In 2017, we leased office space in New York on a month to month basis for $ 300 Beginning November 1, 2015, we subleased an office from a company controlled by our Executive Chairman in Scottsdale, AZ for $ 3,502 Rent expense charged to operations, which differs from rent paid due to rent credits and to increasing amounts of base rent, is calculated by allocating total rental payments on a straight-line basis over the term of the lease. During the years ended December 31, 2017 and 2016, rent expense was $ 144,030 109,340 14,450 14,657 Year ended December 31, 2018 $ 177,450 2019 168,503 2020 119,629 2021 91,466 Total $ 557,048 Employment contracts Dr. Carr Bettis 175,000 The compensation committee following consideration of the report prepared by Farient Advisors LLC established a target number of shares of 2,000,000 (a) satisfaction of a share price condition described below; and (b) 100% achievement of the performance goals by the company and Dr. Bettis, as applicable. Subject to the share price condition, 50% of the target award will be earned by Dr. Bettis at the 85% achievement level, and he can earn up to 150% of the target award at the 125% achievement level. Vesting shall be determined based upon performance measures at the end of each calendar year of 2016 and 2017, with 50% of each target award and performance increase subject to vesting during each performance period. Dr. Bettis shall have the opportunity to achieve full vesting of 100% of the target award and performance increase if there is a shortfall in the first performance period but cumulative performance goals are achieved for the two-year period ending on the measurement date at the end of the second performance period. The number of vested performance options shall be determined for a performance period by reference to the company’s actual achievement against the following performance objectives: (a) Targeted cash contract bookings (as to 33.33%); (b) Targeted net operating cash flow (as to 33.33%); (c) Board defined operations goals (as to 33.33%) for a performance period. And, vesting shall only occur if the closing share price of the company’s common stock on each of the 20 trading days before and including the end of a performance period is not less than $0.20 per share (as adjusted for stock splits, combinations, recapitalization and the like). 268,300 On December 7, 2016, the Company’s Board of Directors approved an extension to and modification of the existing employment contract with Dr. Carr Bettis, as well as the grant of certain equity awards to Dr. Bettis under the Company’s 2016 Incentive Compensation Plan. To best preserve the Company’s limited cash resources, the Employment Contract provides generally that Dr. Bettis’s base compensation is paid in the form of Restricted Stock Units (RSU’s). On December 7, 2016, the Company’s Board of Directors approved an extension to and modification of the existing employment contract with Dr. Carr Bettis, as well as the grant of certain equity awards to Dr. Bettis under the Company’s 2016 Incentive Compensation Plan. To best preserve the Company’s limited cash resources, the Employment Contract provides generally that Dr. Bettis’s base compensation is paid in the form of Restricted Stock Units (RSU’s). In its December 7, 2016 action by written consent, the Company’s Board of Directors approved an award of RSU’s to Dr. Bettis in consideration of services Dr. Bettis rendered subsequent to June 30, 2016. The number of Employment Contract RSUs awarded was 602,620 72,917 0.121 The Board also approved the grant to Dr. Bettis of a long-term equity component of his compensation in the form of an RSU with a seven-year term representing the right to receive, subject to the terms and upon the conditions of the RSU, 250,000 shares of the Company’s Common Stock, with such number of shares to be reduced by the number of shares, if any, that are awarded to Dr. Bettis in connection with the Performance Option Unit Agreement granted Dr. Bettis in January 2016 under the 2016 Plan. This RSU is also subject to the Award Vesting Conditions. On August 10, 2017, the Company amended the terms of the 250,000 The settlement date for such RSUs, as amended, in the earlier of (i) July 1, 2024 or (ii) the date on which the Company undergoes a change of control. The change in vesting terms were considered a modification of equity based instrument and accordingly charged the change in estimated fair value of $ 41,250 On August 10, 2017, the Company amended 402,297 66,379 On August 10, 2017, the Company amended 263,554 43,486 On June 22, 2017, the Company granted to Dr. Bettis 665,000 Todd Bankofier. 250,000 On December 22, 2015, subject to shareholder approval of the 2016 Incentive Compensation Plan the compensation committee following consideration of the report prepared by Farient Advisors LLC of the board approved a performance option agreement for Mr. Bankofier. The number of shares that vest under the performance options are determined based upon the company’s and Mr. Bankofier (as applicable) performance compared to performance goals described below. The compensation committee following consideration of the report prepared by Farient Advisors LLC established a target number of shares of 2,000,000 (a) satisfaction of a share price condition described below; and (b) 100% achievement of the performance goals by the company and Mr. Bankofier, as applicable. Subject to the share price condition, 50% of the target award will be earned by Mr. Bankofier at the 85% achievement level, and he can earn up to 150% of the target award at the 125% achievement level. Vesting shall be determined based upon performance measures at the end of each calendar year of 2016 and 2017, with 50% of each target award and performance increase subject to vesting during each performance period. (a) Targeted cash contract bookings (as to 33.33%); (b) Targeted net operating cash flow (as to 33.33%); (c) Board defined operations goals (as to 33.33%) for a performance period. And, vesting shall only occur if the closing share price of the company’s common stock on each of the 20 trading days before and including the end of a performance period is not less than $0.20 per share (as adjusted for stock splits, combinations, recapitalization and the like). The performance options shall have a term of five years from the date of grant and the exercise price shall be determined by using a 10-day average closing price of the company’s common stock over the ten (10) trading days beginning on January 4, 2016, which the committee has determined to be and the Board agrees is an amount that is not less than the fair market value of a share of the common stock of the company on such date. Effective December 31, 2017, the vesting terms of these options were modified whereby they became fully vested on December 31, 2017. All other option terms remained the same. The incremental increase in the fair value of the options on the date of modification of $ 268,300 On December 7, 2016, the Company’s Board of Directors approved an increase to the base salary of Todd Bankofier, the Company’s Chief Executive Officer. Mr. Bankofier’s base annual salary was increased to $ 175,000 250,000 On August 10, 2017, the Company amended the terms of the 250,000 Sean Bradley 200,000 Pursuant to a Performance Share Unit Agreement, Mr. Bradley was granted an award of an aggregate of 200,000 37.5 1.7 8.0 22 25 75 100,000 300,000 125 93,750 Effective April 24, 2015, our board of directors appointed Sean Bradley to serve as President of our company as well as continuing as Chief Technology Officer and Secretary. Effective May 1, 2015, Mr. Bradley agreed to reduce his annual base salary to $ 150,000 6,250 The compensation committee following consideration of the report prepared by Farient Advisors LLC established a target number of shares of 1,500,000 (a) satisfaction of a share price condition described below; and (b) 100% achievement of the performance goals by the company and Mr. Bradley, as applicable. Subject to the share price condition, 50% of the target award will be earned by Mr. Bradley at the 85% achievement level, and he can earn up to 150% of the target award at the 125% achievement level. Vesting shall be determined based upon performance measures at the end of each calendar year of 2016 and 2017, with 50% of each target award and performance increase subject to vesting during each performance period. (a) Targeted cash contract bookings (as to 33.33%); (b) Targeted net operating cash flow (as to 33.33%); (c) Board defined operations goals (as to 33.33%) for a performance period. And, vesting shall only occur if the closing share price of the company’s common stock on each of the 20 trading days before and including the end of a performance period is not less than $0.20 per share (as adjusted for stock splits, combinations, recapitalization and the like). 201,225 The Board following consideration of the report prepared by Farient Advisors LLC also approved the grant to Mr. Bradley of a long-term equity component of his compensation in the form of an RSU with a seven-year term representing the right to receive, subject to the terms and upon the conditions of the RSU, 150,000 On August 10, 2017, the Company amended the terms of the 150,000 Litigation In April 2015, two shareholder class action lawsuits were filed against the Company and former officers Nathaniel Bradley and Edward O’Donnell in the U.S. District Court for the District of Arizona. The plaintiffs alleged various causes of action against the defendants arising from our announcement that our previously issued financial results for the first three quarters of 2014 and the guidance for the fourth quarter of 2014 and the full year of 2014 could no longer be relied upon. The complaints sought among other relief, compensatory damages and plaintiff’s counsel’s fees and experts’ fees. The Court appointed a lead plaintiff and lead counsel, and consolidated the actions. A consolidated amended complaint was filed under the caption In re AudioEye, Inc. Sec. Litigation. On July 25, 2016, in connection with a voluntary mediation, the parties reached an agreement in principle to settle the consolidated actions. The terms of the agreement include a settlement payment to the class of $ 1,525,000 100,000 On January 23, 2017, the court granted preliminary approval of the settlement pursuant to the terms set forth in the Stipulation of Settlement, provisionally certified a settlement class of shareholders, and directed plaintiffs' counsel to provide notice to that class. The Court held a Settlement Hearing May 8, 2017 to consider any objections to the Settlement that might be raised by settlement class members, to consider plaintiffs’ counsel's application for an award of fees and costs, and to determine whether the Order and Final Judgment as provided under the Stipulation of Settlement should be entered, dismissing the case with prejudice. On May 8, 2017, this Court granted final approval to the settlement of the securities class action brought by Lead Plaintiffs, individually and on behalf of all others similarly situated. On February 9, 2018, the Court authorized distribution of the Net Settlement Fund and to approved the proposed modified plan of allocation. On May 16, 2016, a shareholder derivative complaint entitled LiPoChing, Derivatively and on Behalf of AudioEye, Inc., v. Bradley, et al., was filed in the United States District Court for the District of Arizona. As a derivative complaint, the plaintiff-shareholder purported to act on behalf of the Company against the Named Individuals. The Company was named as a nominal defendant. The complaint asserted causes of action including breach of fiduciary duty and others, arising from the Company’s restatement of its financial results for the first three quarters of 2014. The complaint sought, among other relief, compensatory damages, restitution and attorneys’ fees. In October 2016, the Company and Named Defendants filed a motion to dismiss. In response, the Plaintiff voluntarily dismissed the complaint without prejudice. Plaintiff’s counsel subsequently submitted a demand to the Company’s Board of Directors, to investigate the circumstances surrounding restatement of its financial results for the first three quarters of 2014. The Board has formed an Independent Director lead special litigation committee to evaluate the demand and make a recommendation to the Board. No determination has been made at this time. On July 26, 2016, a shareholder derivative complaint entitled Denese M. Hebert, derivatively on Behalf of Nominal Defendant AudioEye, Inc., v. Bradley, et al., was filed in the State of Arizona Superior Court for Pima County. The complaint generally asserted causes of action related to the Company’s restatement of its financial statements for the first three fiscal quarters of 2014. As a derivative complaint, the plaintiff-shareholder purported to act on behalf of the Company against the Named Individuals. The Company was named as a nominal defendant. The defendants filed a motion to dismiss, which the Court granted on May 8, 2017, while also denying Plaintiff’s request for leave to amend the complaint. As in the above matter, after this matter was dismissed Plaintiff’s counsel subsequently submitted a demand to the Company’s Board of Directors, to investigate the circumstances surrounding restatement of its financial results for the first three quarters of 2014. While the Company believes that its legal defense costs may be reimbursed by the Company’s insurance carrier, no reasonable estimate of the outcome of the litigation, the related legal fees, or the impact on the financial results of the Company can be made as of the date of this statement. This demand is being evaluated together with the above demand by the Board’s Independent Director lead special litigation committee. No determination has been made at this time. We may become involved in various other routine disputes and allegations incidental to our business operations. While it is not possible to determine the ultimate disposition of these matters, our management believes that the resolution of any such matters, should they arise, is not likely to have a material adverse effect on our financial position or results of operations.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2017
Stockholders' Equity Attributable to Parent [Abstract]
Sale Leaseback Transaction Disclosure [Text Block]	NOTE 10 — STOCKHOLDERS’ EQUITY Preferred stock As of December 31, 2017 and 2016, the Company had 110,000 160,000 10 5 0.1754 75,206 80,000 428,783 442,372 146,918 133,699 837,617 762,252 Common stock As of December 31, 2017 and 2016, the Company had 161,664,077 111,521,001 In April 2016, the Company issued an aggregate 83,336 14,292 In April 2016, the Company issued an aggregate of 12,834,800 1,025,000 53,123 In May 2016, the Company sold an aggregate of 11,714,285 1,312,000 1,579,082 63,292 0.25 In May 2016, the Company issued 900,525 15,000 In July 2016, the Company issued an aggregate 124,998 20,666 In August 2016, the Company issued an aggregate 41,666 6,208 In September 2016, the Company issued an aggregate 41,666 6,292 In October 2016, the Company issued an aggregate 41,666 5,208 In November 2016, the Company issued an aggregate 41,666 4,917 In December 2016, the Company issued an aggregate 41,666 5,709 In December 2016, the Company sold an aggregate of 3,928,573 440,000 550,000 0.25 In January 2017, the Company sold 357,143 40,000 50,000 0.25 In January 2017, the Company issued 41,666 6,625 In February 2017, the Company issued 41,666 5,333 In March 2017, the Company issued 41,666 5,917 In April 2017, the Company issued 41,674 7,126 In May 2017, the Company issued 528,302 1,000,000 In October 2017, the Company sold an aggregate of 10,714,286 1,500,000 0.14 In October 2017, the Company issued 3,204,027 50,000 In November 2017, the Company issued an aggregate of 2,250,000 157,500 In November 2017, the Company issued an aggregate of 1,530,292 102,836 In November 2017, the Company issued 1,078,947 2,000,000 In December 2017, the Company issued an aggregate of 750,000 52,500 In December 2017, the Company issued an aggregate of 11,346,726 762,500 In December 2017, the Company issued 18,225,681 18,353,310 Registration rights Under the purchase agreement, the Company has agreed to use its reasonable best efforts to prepare and file with the SEC registration statement within 60 days of the initial closing date, covering the resale by the investors of any common stock previously issued to the investors, and any common stock into which any convertible promissory notes previously issued to the investors are convertible and any common stock for which the warrants or any warrants previously issued to the investors are exercisable. The Company filed a registration statement on September 30, 2016 and became effective on December 21, 2016. Options 25,095,557 25,731,207 Intrinsic Wtd Avg. Value Number of Wtd Avg. Remaining of Options Exercise Price Term Exercisable Options Outstanding at December 31, 2015 14,759,914 $ 0.30 3.61 8,374,294 $ 235,330 Granted 12,508,877 0.09 4.87 - Forfeited/Expired (1,537,584) 0.29 Outstanding at December 31, 2016 25,731,207 $ 0.20 3.34 15,091,366 $ 1,161,244 Granted 1,450,000 0.16 5.00 - Forfeited/Expired (2,085,650) 0.34 — Outstanding at December 31, 2017 25,095,557 $ 0.19 2.64 22,276,224 $ 1,356,188 On January 15, 2016, the Company granted performance options to acquire shares of the Company’s common stock in aggregate of 6,500,000 0.038 Vesting shall only occur if the closing share price of the Company’s common stock on each of the 20 trading days before and including the end of any performance period is not less than $0.20 per share (market condition) 5,500,000 The estimated fair values of the options with performance and market conditions were determined using a Monte Carlo pricing model. Significant assumptions used in the valuation include expected term of 5 162 1.46 0 Nonperformance option grants during the year ended December 31, 2016 were valued using the Black-Scholes pricing model. Significant assumptions used in the valuation include expected term of 1.5 3.5 102.00 176.77 0.87 1.73 0 On January 4, 2016, the Company issued 500,000 150,000 0.038 January 4, 2019 On April 15, 2016, the Company issued 49,715 0.179 April 15, 2019 6,250 On May 12, 2016, the Company issued 100,000 50 4.17 0.177 May 12, 2021 16,694 On May 12, 2016, the Company issued an aggregate of 3,400,000 50 50 0.177 May 12, 2021 559,603 On June 15, 2016, the Company issued 300,000 50 th June 15, 2021 40,723 On July 15, 2016, the Company issued 56,375 0.156 July 15, 2019 6,250 On October 15, 2016, the Company issued 61,599 0.121 October 15, 2019 5,209 On December 2, 2016, the Company issued an aggregate of 1,391,188 50 25 25 0.121 150,875 On January 17, 2017, the Company granted 100,000 50 2.08 0.159 January 17, 2022 11,119 On March 10, 2017, the Company granted 100,000 50 2.08 0.145 March 10, 2022 12,541 On July 10, 2017, the Company granted 1,250,000 1,000,000 0.166 1,000,000 options vested immediately and 250,000 options vest 50% after approximately nine months, with an additional 4.17% vesting every month thereafter Option grants during the year ended December 31, 2017 were valued using the Black-Scholes pricing model. Significant assumptions used in the valuation include expected term of 2.50 3.50 169.46 175.56 1.42 1.66 0 Effective December 31, 2017, 5,500,000 100 58,830 737,825 1.52 163.87 1.76 0 For the year ended December 31, 2017 and 2016, total stock compensation expense related to the options totaled $ 1,236,863 864,024 The outstanding unamortized stock compensation expense related to options was $ 111,996 Warrants Intrinsic Wtd Avg. Value Number of Wtd Avg. Remaining of Warrants Exercise Price Term Warrants Outstanding at December 31, 2015 43,246,858 $ 0.22 4.15 $ 1,167 Granted 21,681,264 0.03 4.87 - Forfeited (1,495,081) 0.48 - Outstanding at December 31, 2016 63,433,041 $ 0.15 3.55 $ 3,662,610 Granted 9,165,000 0.10 4.89 — Exercised (24,353,310) 0.03 Forfeited/Expired (247,396) 0.49 — Outstanding at December 31, 2017 47,997,335 $ 0.20 2.61 $ 1,656,083 The warrant grants during the year ended December 31, 2016 were valued using the Black-Scholes pricing model. Significant assumptions used in the valuation include expected term of 1.5 2.5 166.74 178.98 0.71 1.08 0 During the year ended December 31, 2016, the Company issued an aggregate of 1,575,954 0.038 0.179 150,500 1,575,954 1,492,620 In April 2016, the Company issued an aggregate of 18,353,310 1,541,678 0.001 The Company determined that the estimated fair value of the 18,353,310 3,205,959 1,541,678 1,664,281 0.175 178 1.24 5 In May 2016, the Company issued 1,312,000 0.25 In December 2016, the Company issued 440,000 0.25 In January 2017, the Company issued 40,000 0.25 In January 2017, in exchange for services rendered, the Company issued 250,000 0.12 29,433 In April 2017, the Company issued 500,000 0.10 In October 2017, in exchange for services rendered, the Company issued 250,000 0.179 33,785 In October and November 2017, the Company issued an aggregate of 8,125,000 0.10 The warrant grants for services during the year ended December 31, 2017 were valued using the Black-Scholes pricing model. Significant assumptions used in the valuation include expected term of 3.0 175.64 1.48 0 For the year ended December 31, 2017 and 2016, the Company has incurred warrant-based expense of $ 109,509 221,621 1,393 Restricted stock units (“RSU”) Restricted shares issued as of January 1, 2016 - Granted 1,252,620 Total Restricted Shares Issued at December 31, 2016 1,252,620 Granted 2,655,851 Total Restricted Shares Issued at December 31, 2017 3,908,471 Vested at December 31, 2017 1,918,471 Unvested restricted shares as of December 31, 2017 1,990,000 On December 7, 2016, the Company following consideration of the report prepared by Farient Advisors LLC granted 602,620 72,917 The Board also approved following consideration of the report prepared by Farient Advisors LLC the grant to an aggregate of 650,000 RSUs to officers with a seven-year term representing the right to receive, subject to the terms and upon the conditions of the RSU, 650,000 shares of the Company’s common stock, with such number of shares to be reduced by the number of shares, if any, that are awarded to Dr. Bettis in connection with the Performance Option Unit Agreement granted Dr. Bettis in January 2016 under the 2016 Plan. These RSU is also subject the following conditions: (i) Officer remains in service to the Company continuously through and until June 30, 2017, and (ii) the Company undergoes a change of control during the seven-year term of the award. The fair value of the 650,000 87,750 In connection with the issuance of the above described RSUs as payment for accrued compensation, the Company reclassified to equity the outstanding salary accrual of $ 72,917 On August 10, 2017, the Company amended 402,297 66,379 On August 10, 2017, the Company amended 263,554 43,486 In connection with the issuance of the above described RSUs as payment for accrued compensation, the Company reclassified to equity the settled aggregate salary accrual of $ 102,083 7,782 14,583 87,500 26,515 On June 22, 2017, the Company following consideration of the report prepared by Farient Advisors LLC granted 665,000 On August 10, 2017, the Company following consideration of the report prepared by Farient Advisors LLC granted 415,000 40,000 1,325,000 On August 10, 2017, the Company amended the terms of an aggregate of 650,000 107,250 For the year ended December 31, 2017 and 2016, the Company has incurred RSU-based expense of $ 418,832 14,583 404,249 0 178,115

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 11 — INCOME TAXES The Company accounts for income taxes under ASC 740, “Income Taxes”. Temporary differences are differences between the tax basis of assets and liabilities and their reported amounts in the financial statements that will result in taxable or deductible amounts in future years. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is recorded when the ultimate realization of a deferred tax as The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities are presented below: Deferred tax assets: 2017 2016 Net operating loss carry forwards $ 5,014,461 $ 7,558,530 Less valuation allowance (5,014,461) (7,558,530) Net deferred tax asset $ - $ - At this time, the Company is unable to determine if it will be able to benefit from its deferred tax asset. There are limitations on the utilization of net operating loss carry forwards, including a requirement that losses be offset against future taxable income, if any. In addition, there are limitations imposed by certain transactions, which are deemed to be ownership changes. Accordingly, a valuation allowance has been established for the entire deferred tax asset. The approximate net operating loss carry forward was $ 23,878,387 22,716,669 On December 22, 2017, the Tax Act was signed into law making significant changes to the Internal Revenue Code. Changes include, but are not limited to, a corporate tax rate decrease from 35 21

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 12 — SUBSEQUENT EVENTS On March 9, 2018, the Company granted an aggregate of 1,537,339 959,839 327,500 250,000

SIGNIFICANT ACCOUNTING POLICI20

SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Empire Technologies, LLC (“Empire”). All significant inter-company accounts and transactions have been eliminated. During the years ended December 31, 2017 and 2016, Empire had no activity. Empire had no assets or liabilities as of December 31, 2017 and December 31, 2016. The Company acquired 19.5
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Revenue is recognized when all applicable recognition criteria have been met, which generally include (a) persuasive evidence of an existing arrangement; (b) fixed or determinable price; (c) delivery has occurred or service has been rendered; and (d) collectability of the sales price is reasonably assured. For software and technology development contracts the Company recognizes revenues on a percentage of completion method based upon several factors including but not limited to (a) estimate of total hours and milestones to complete; (b) total hours completed; (c) delivery of services rendered; (d) change in estimates; and (e) collectability of the contract. The Company had two major customers including their affiliates which generated approximately 28.4 18.0 10.4 The Company had two major customers including their affiliates which generated approximately 45.3 23.8 21.5 At December 31, 2017, the Company had five customers representing 18 14 14 13 10 69 29 18 47 Certain Software as a Service (SaaS) are prepared and invoiced on an annual basis. Any funds received for services not provided yet are held in deferred revenue, and are recorded as revenue when earned.
Research, Development, and Computer Software, Policy [Policy Text Block]	In accordance with ASC 350-40, the Company capitalizes certain computer software and software development costs incurred in connection with developing or obtaining computer software for internal use when both the preliminary project stage is completed and it is probable that the software will be used as intended. Capitalized software costs include only (i) external direct costs of materials and services utilized in developing or obtaining computer software, (ii) compensation and related benefits for employees who are directly associated with the software project and (iii) any interest costs incurred while developing internal-use computer software. Capitalized software costs are included in intangible assets on our balance sheet and amortized on a straight-line basis when placed into service over the estimated useful lives of the software (see Note 6).
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of the Company’s stock, stock-based compensation, fair values relating to derivative liabilities, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Research and Development Expense, Policy [Policy Text Block]	Research and Technology Expenses Research and technology expenses are expensed in the period costs are incurred. For the year ended December 31, 2017 and 2016, research and technology expenses totaled $ 181,303 343,712
Fiscal Period, Policy [Policy Text Block]	Fiscal Year End The Company has a fiscal year ending on December 31.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers cash in savings accounts to be cash equivalents. The Company considers any short-term, highly liquid investments with maturities of three months or less as cash and cash equivalents.
Marketable Securities, Policy [Policy Text Block]	Marketable Securities The Company has elected the fair value option under ASC 825 for its marketable securities. Marketable securities are classified as available for sale and consist of common stock holdings of publicly traded companies. These securities are marked to market at the end of each reporting period based on the closing price of the security at each balance sheet date. Changes in fair value are recorded as unrealized gains or losses in the consolidated statement of operations in accordance with ASC 320.
Cost Method Investments, Policy [Policy Text Block]	Non-marketable Securities From time to time, the Company invests in the securities of other entities where there exists no active market for the securities held. Non-marketable securities are recorded at the cost of the investment.
Receivables, Policy [Policy Text Block]	Allowance for Doubtful Accounts The Company establishes an allowance for bad debts through a review of several factors including historical collection experience, current aging status of the customer accounts, and financial condition of the Company’s customers. The Company does not generally require collateral for its accounts receivable. During the years ended December 31, 2017 and 2016, the Company incurred $ 3,202 0 0
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are carried at the cost of acquisition or construction and depreciated over the estimated useful lives of the assets. Costs associated with repairs and maintenance are expensed as incurred. Costs associated with improvements which extend the life, increase the capacity or improve the efficiency of the Company’s property and equipment are capitalized and depreciated over the remaining life of the related asset. Gains and losses on dispositions of equipment are reflected in operations. Depreciation is provided using the straight-line method over the estimated useful lives of the assets, which are 5 7
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill, Intangible Assets, and Long-Lived Assets Goodwill is carried at cost and is not amortized. The Company tests goodwill for impairment on an annual basis at the end of each fiscal year, relying on a number of factors including operating results, business plans, economic projections, anticipated future cash flows and marketplace data. Company management uses its judgment in assessing whether goodwill has become impaired between annual impairment tests according to specifications set forth in ASC 350. The Company completed an evaluation of goodwill at December 31, 2017 and 2016 and determined that there was no impairment. The fair value of the Company’s reporting unit is dependent upon the Company’s estimate of future cash flows and other factors. The Company’s estimates of future cash flows include assumptions concerning future operating performance and economic conditions and may differ from actual future cash flows. Estimated future cash flows are adjusted by an appropriate discount rate derived from the Company’s market capitalization plus a suitable control premium at date of the evaluation. The financial and credit market volatility directly impacts the Company’s fair value measurement through the Company’s weighted average cost of capital that the Company uses to determine its discount rate and through the Company’s stock price that the Company uses to determine its market capitalization. Therefore, changes in the stock price may also affect the amount of impairment recorded. The Company recognizes an acquired intangible asset apart from goodwill whenever the intangible asset arises from contractual or other legal rights, or when it can be separated or divided from the acquired entity and sold, transferred, licensed, rented or exchanged, either individually or in combination with a related contract, asset or liability. Such intangibles are amortized over their useful lives. Impairment losses are recognized if the carrying amount of an intangible asset subject to amortization is not recoverable from expected future cash flows and its carrying amount exceeds its fair value. The Company reviews its long-lived assets, including property and equipment, identifiable intangibles, and goodwill annually or whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of its long-lived assets, the Company evaluates the probability that future undiscounted net cash flows will be less than the carrying amount of the assets.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company’s long-lived assets, including intangibles, are reviewed for impairment whenever events or changes in circumstances indicate that the historical-cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the asset by comparing the undiscounted future net cash flows expected to result from the asset to its carrying value. If the carrying value exceeds the undiscounted future net cash flows of the asset, an impairment loss is measured and recognized. An impairment loss is measured as the difference between the net book value and the fair value of the long-lived asset. Long-lived assets were evaluated for impairment and no impairment losses were incurred during the years ended December 31, 2017 and 2016, respectively.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock based compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the consolidated statements of operations, as if such amounts were paid in cash.
Income Tax, Policy [Policy Text Block]	Income Taxes Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. These assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to reverse. The Company has net operating loss carryforwards available to reduce future taxable income. Future tax benefits for these net operating loss carryforwards are recognized to the extent that realization of these benefits is considered more likely than not. To the extent that the Company will not realize a future tax benefit, a valuation allowance is established. Basic earnings (loss) per share are computed by dividing net income, or loss, by the weighted average number of shares of common stock outstanding for the period. Diluted earnings (loss) per share and basic earnings (loss) per share are not included in the net loss per share computation until the Company has Net Income. Diluted loss per share including the dilutive effects of common stock equivalents on an “as if converted” basis would reduce the loss per share and thereby be antidilutive.
Earnings Per Share, Policy [Policy Text Block]	Earnings (Loss) Per Share 2017 2016 Preferred stock 7,108,996 9,122,007 Options to purchase common stock 25,095,557 25,731,207 Warrants to purchase common stock 47,997,335 63,433,041 Restricted stock units 3,908,471 1,252,620 Totals 84,110,359 99,538,875
Derivatives, Policy [Policy Text Block]	Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedging relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2017 and 2016, the Company did not have any derivative instruments that were designated as hedges. On October 9, 2015, the Company issued convertible promissory notes representing $ 2,500,000 25,000,000 0.10 5 50,000 500,000 In addition, in 2016 and 2017, in connection with the sale of the Company’s common stock, the Company issued warrants exercisable for up to 1,792,000 0.25 5 In accordance with ASC 815, these outstanding warrants are deemed to be derivatives. The value of the derivative instrument will fluctuate with the price of the Company’s common stock and is recorded as a current liability on the Company’s Consolidated Balance Sheets. The change in the value of the liability is recorded as “unrealized gain (loss) on derivative liability” on the Consolidated Statements of Operations. This is a non-cash income (expense) item and is adjusted in the “operating activities” of the Consolidated Statements of Cash Flow. At December 31, 2017 and 2016, the derivative liability was stated at $ 2,984,010 3,478,626 155,027
Fair Value of Financial Instruments, Policy [Policy Text Block]	Financial Instruments The carrying amount of the Company’s financial instruments, consisting of cash equivalents, short-term investments, account and notes receivable, accounts and notes payable, short-term borrowings and certain other liabilities, approximate their fair value due to their relatively short maturities. The carrying amount of the Company’s long-term debt approximates fair value since the stated rate of interest approximates a market rate of interest.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements Fair value is an estimate of the exit price, representing the amount that would be received to upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants (i.e., the exit price at the measurement date). Fair value measurements are not adjusted for transaction cost. Fair value measurement under generally accepted accounting principles provides for use of a fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value into three levels: Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than quoted market prices that are observable, either directly or indirectly, and reasonably available. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the Company. Level 3: Unobservable inputs reflect the assumptions that the Company develops based on available information about what market participants would use in valuing the asset or liability. An asset or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and liabilities and Level 3 assets and liabilities involve greater judgment than Level 1 and Level 2 assets or liabilities. In October and November 2015 and April 2017, the Company issued warrants with an exercise price of $ 0.10 0.10 The Company estimated the fair value of these derivative warrants at initial issuance and again at each balance sheet date. The changes in fair value are recognized in earnings in the Consolidated Statements of Operations under the caption “unrealized gain/(loss) – derivative liability” until such time as the derivative warrants are exercised or expire. The Company used the Black-Scholes Option Pricing model to estimate the fair value as of the dates of issuance, the price of the Company stock ranged $ 0.031 0.187 102 172 1.14 1.79 5 In 2016 and 2017, the Company issued warrants with an exercise price of $ 0.25 0.25 The Company estimated the fair value of these derivative warrants at initial issuance and again at each balance sheet date. The changes in fair value are recognized in earnings in the Consolidated Statements of Operations under the caption “unrealized gain/ (loss) – derivative liability” until such time as the derivative warrants are exercised or expire. The Company used the Black-Scholes Option Pricing model to estimate the fair value and as of the dates of issuance, the price of the Company stock ranged $ 0.152 0.195 169 178 1.22 1.87 5 280,777 6,062 On May 2, 2017, a warrant holder exercised a warrant to acquire 1,000,000 0.20 171 1.45 3.4 184,569 In October and November 2017, the Company offered, as an inducement to exercise, to reduce the exercise price of previously issued warrants from $0.10 per share to $ 0.07 0.139 0.1549 165 166 1.60 1.99 2.94 4.42 13,262 574,342 At December 31, 2017, the price of the Company stock was $ 0.1549 163.9 1.98 2.20 2.77 4.03 2,984,010 155,027 Fair Value Fair Value Hierarchy Assets Marketable securities, December 31, 2017 $ 750 Level 1 Marketable securities, December 31, 2016 $ 1,200 Level 1 Liabilities Derivative Liability , December 31, 2017 $ 2,984,010 Level 3 Derivative Liability , December 31, 2016 $ 3,478,626 Level 3
New Accounting Pronouncements, Policy [Policy Text Block]	Adoption of Accounting Standards In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company anticipates early adoption of this pronouncement effective January 1, 2018. As such, the impact would the reclassification of the December 31, 2017 fair values of our warrant and derivative liabilities to equity. On January 1, 2018, the Company adopted ASU 2017-11 by electing the retrospective method to the outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the statement of financial position as of the beginning of the fiscal year. Accordingly, the Company reclassified the fair value of the reset provisions embedded in previously issued warrants with embedded anti-dilutive provisions from liability to equity (accumulated deficit) in aggregate of $ 2,984,010 In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. The updated guidance states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also provides for additional disclosures with respect to revenues and cash flows arising from contracts with customers. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017, and the Company will adopt the standard using the modified retrospective approach effective January 1, 2018. The most significant impact of the standard relates to capitalizing costs to acquire contracts, which have historically been expensed as incurred. As of December 31, 2017, the Company’s sales commission plans have included multiple payments, including initial payments in the period a customer contract is obtained and deferred payments over the life of the contract as future payments are collected from the customers. Under the standard, only the initial payment is subject to capitalization as the deferred payments require a substantive performance condition of the employee. These initial commission payments will be capitalized in the period a customer contract is obtained and will be amortized consistent with the transfer of the goods or services to the customer over the expected period of benefit. The expected period of benefit is the contract term, except when the commission payment is expected to provide economic benefit to the Company for a period longer than the contract term, such as for new customer or incremental sales where renewals are expected and renewal commissions are not commensurate with initial commissions. Such commissions will be amortized over the greater of contract term or technological obsolescence period when the underlying contracted products are technology-based, such as for the SaaS-based platforms, or the expected customer relationship period when the underlying contracted products are not technology-based, such as for patient experience survey products. The Company has determined that the adoption of ASU-2014-09 will not have a material impact on its consolidated financial statements. There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.

SIGNIFICANT ACCOUNTING POLICI21

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Potentially dilutive securities excluded from the computation of basic and diluted net earnings (loss) per share are as follows: 2017 2016 Preferred stock 7,108,996 9,122,007 Options to purchase common stock 25,095,557 25,731,207 Warrants to purchase common stock 47,997,335 63,433,041 Restricted stock units 3,908,471 1,252,620 Totals 84,110,359 99,538,875
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following are the Company’s assets and liabilities, measured at fair value on a recurring basis, as of December 31, 2017 and 2016: Fair Value Fair Value Hierarchy Assets Marketable securities, December 31, 2017 $ 750 Level 1 Marketable securities, December 31, 2016 $ 1,200 Level 1 Liabilities Derivative Liability , December 31, 2017 $ 2,984,010 Level 3 Derivative Liability , December 31, 2016 $ 3,478,626 Level 3

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment as of December 31, 2017 and 2016 is summarized as follows: 2017 2016 Computer equipment $ 63,517 $ 25,478 Furniture and fixtures 3,128 - Total 66,645 25,478 Less accumulated depreciation (31,651) (25,478) Property and equipment, net $ 34,994 $ -

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Prior to any impairment adjustment, intangible assets consisted of the following: 2017 2016 Patents $ 3,697,709 $ 3,697,710 Capitalized software development 1,005,369 621,566 Accumulated amortization (2,538,615) (2,006,027) Intangible assets, net $ 2,164,463 $ 2,313,249

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Payable [Abstract]
Schedule of Debt [Table Text Block]	As of December 31, 2017 and 2016, the Company has short term notes payable of $- 0 23,800 Notes and loans payable 2017 2016 Short Term Maryland TEDCO $ - $ 23,800 Total $ - $ 23,800

COMMITMENTS AND CONTINGENCIES(T

COMMITMENTS AND CONTINGENCIES(Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	The following is a schedule of future minimum lease payments for all non-cancelable operating leases for each of the next four years ending December 31 and thereafter: Year ended December 31, 2018 $ 177,450 2019 168,503 2020 119,629 2021 91,466 Total $ 557,048

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	12 Months Ended
	Dec. 31, 2017
Stockholders' Equity Attributable to Parent [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	As of December 31, 2017 and 2016, the Company has outstanding options to purchase 25,095,557 25,731,207 Intrinsic Wtd Avg. Value Number of Wtd Avg. Remaining of Options Exercise Price Term Exercisable Options Outstanding at December 31, 2015 14,759,914 $ 0.30 3.61 8,374,294 $ 235,330 Granted 12,508,877 0.09 4.87 - Forfeited/Expired (1,537,584) 0.29 Outstanding at December 31, 2016 25,731,207 $ 0.20 3.34 15,091,366 $ 1,161,244 Granted 1,450,000 0.16 5.00 - Forfeited/Expired (2,085,650) 0.34 — Outstanding at December 31, 2017 25,095,557 $ 0.19 2.64 22,276,224 $ 1,356,188
Schedule of Other Share-based Compensation, Activity [Table Text Block]	Below is a table summarizing the Company’s outstanding warrants as of December 31, 2017 and 2016: Intrinsic Wtd Avg. Value Number of Wtd Avg. Remaining of Warrants Exercise Price Term Warrants Outstanding at December 31, 2015 43,246,858 $ 0.22 4.15 $ 1,167 Granted 21,681,264 0.03 4.87 - Forfeited (1,495,081) 0.48 - Outstanding at December 31, 2016 63,433,041 $ 0.15 3.55 $ 3,662,610 Granted 9,165,000 0.10 4.89 — Exercised (24,353,310) 0.03 Forfeited/Expired (247,396) 0.49 — Outstanding at December 31, 2017 47,997,335 $ 0.20 2.61 $ 1,656,083
Nonvested Restricted Stock Shares Activity [Table Text Block]	The following table summarizes the restricted stock activity for the two years ended December 31, 2017: Restricted shares issued as of January 1, 2016 - Granted 1,252,620 Total Restricted Shares Issued at December 31, 2016 1,252,620 Granted 2,655,851 Total Restricted Shares Issued at December 31, 2017 3,908,471 Vested at December 31, 2017 1,918,471 Unvested restricted shares as of December 31, 2017 1,990,000

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Deferred tax assets: 2017 2016 Net operating loss carry forwards $ 5,014,461 $ 7,558,530 Less valuation allowance (5,014,461) (7,558,530) Net deferred tax asset $ - $ -

ORGANIZATION (Details Textual)

ORGANIZATION (Details Textual)	1 Months Ended
	Dec. 30, 2013USD ($)shares	Mar. 22, 2013USD ($)shares	Aug. 17, 2012
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Merger With Aeac Conversion Rate Of Stock		0.94134
Affiliate Of C M G Holdings Groups Inc [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Debt Instrument, Decrease, Forgiveness	$ 50,000
Audio Eye Acquisition Corporation [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Sale of Stock, Percentage of Ownership after Transaction			80.00%
Debt Conversion Accrued Interest On Debt Amount1		$ 67,732
Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued To Debenture Holders | shares		5,871,752
Debt Conversion, Original Debt, Amount		$ 1,400,200
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares		24,004,143
C M G Holdings Group Inc [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Spin Off Stock holders Dividend			5.00%
Royalty Percentage Separation And Spin Off			10.00%
Commission Percentage Separation And Spin Off			7.50%
Commission Percentage Separation And Spin Off Specified			10.00%
Sale of Stock, Percentage of Ownership after Transaction			80.00%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners			15.00%
Stock Repurchased and Retired During Period, Shares | shares	2,184,583
Stock Repurchased During Period, Value	$ 573,022

GOING CONCERN AND MANAGEMENT_29

GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS (Details Textual) - USD ($)	Apr. 11, 2017	Nov. 30, 2017	Apr. 30, 2016	Dec. 31, 2017	Dec. 31, 2016
Going Concern And Management Liquidity Plans [Line Items]
Working Capital Amount				$ 2,198,926
Working Capital				785,084
Cash				1,960,430	$ 1,409,418
Net Cash Provided by (Used in) Operating Activities				(1,622,719)	(2,340,281)
Proceeds from Issuance or Sale of Equity				$ 1,550,000
Stock Issued During Period, Shares, Conversion of Convertible Securities		786,244	12,834,800	2,198,926
Proceeds from Warrant Exercises		$ 157,500		$ 785,084
Proceeds from Convertible Debt	$ 50,000			$ 862,500	$ 0

SIGNIFICANT ACCOUNTING POLICI30

SIGNIFICANT ACCOUNTING POLICIES (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	84,110,359	99,538,875
Preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,108,996	9,122,007
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	25,095,557	25,731,207
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	47,997,335	63,433,041
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,908,471	1,252,620

SIGNIFICANT ACCOUNTING POLICI31

SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities held in related party	$ 750	$ 1,200
Fair Value, Inputs, Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities held in related party	750	1,200
Fair Value, Inputs, Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Notional Amount		$ 3,478,626
Derivative Liability, Fair Value, Gross Liability	$ 2,984,010

SIGNIFICANT ACCOUNTING POLICI32

SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($)	Jan. 01, 2018	Oct. 11, 2017	May 02, 2017	Oct. 09, 2015	Nov. 30, 2017	Oct. 31, 2017	Apr. 30, 2017	Jan. 31, 2017	Dec. 31, 2016	May 31, 2016	Nov. 30, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2012	Apr. 11, 2017	Apr. 30, 2016
Summary Of Significant Accounting Policies [Line Items]
Payments to Acquire Businesses and Interest in Affiliates, Total												$ 2,984,010
Research and Development Expense, Total												$ 181,303	$ 343,712
Concentration Risk, Percentage												69.00%
Allowance for Doubtful Accounts Receivable									$ 0			$ 0	0
Common Stock Issuance Price Per Share											$ 0.10	$ 0.25
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.10	$ 0.07			$ 0.25		$ 0.25	$ 0.10	0.25				$ 0.001
Share Price			$ 0.20									$ 0.1549
Fair Value Assumptions, Weighted Average Volatility Rate			171.00%									163.90%
Fair Value Assumptions, Risk Free Interest Rate			1.45%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				5 years							5 years	5 years
Fair Value Adjustment of Warrants					$ 13,262							$ 13,262	0
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Change in Unrealized Gain (Loss)												155,027
Class Of Warrant Or Right Exercisable Number				25,000,000
Stock Issued During Period Value Warrants Exercised				1,792,000		1,500,000				1,312,000
Debt Instrument, Face Amount				$ 2,500,000
Derivative Liability, Current									$ 3,478,626			2,984,010	3,478,626
Unrealized Gain (Loss) on Derivatives												(155,027)	(2,758,488)
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,000,000		8,125,000
Fair Value Assumptions, Expected Term		5 years	3 years 4 months 24 days		5 years
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity			$ 184,569									6,062	280,777
Provision for Doubtful Accounts												3,202	$ 0
Reclassify Fair Value Of Liability Warrant Equity Upon Exercise					$ 574,342
Subsequent Event [Member] | Accounting Standards Update 2017-11 [Member]
Summary Of Significant Accounting Policies [Line Items]
Reclassify Fair Value Of Liability Warrant Equity Upon Exercise	$ 2,984,010
Note and Warrant Purchase Agreement [Member]
Summary Of Significant Accounting Policies [Line Items]
Debt Instrument, Face Amount															$ 50,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights															500,000
Warrant [Member]
Summary Of Significant Accounting Policies [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.25		$ 0.179	$ 0.10	$ 0.25	$ 0.25	$ 0.25			$ 0.25
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				5 years
Fair Value Adjustment of Warrants												$ 6,062	$ 280,777
Stock Issued During Period Value Warrants Exercised							500,000	40,000	440,000	1,312,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									1,575,954			1,575,954	1,575,954
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life												5 years
Share Price					$ 0.139						$ 0.031
Fair Value Assumptions, Weighted Average Volatility Rate											102.00%
Fair Value Assumptions, Risk Free Interest Rate		1.60%			1.60%						1.14%	1.98%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period												2 years 9 months 7 days
Fair Value Assumptions, Expected Term					2 years 11 months 8 days
Fair Value Assumptions, Expected Volatility Rate		165.18%			165.00%
Minimum [Member] | Warrant [Member]
Summary Of Significant Accounting Policies [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights												$ 0.038
Share Price												$ 0.152
Fair Value Assumptions, Weighted Average Volatility Rate												169.00%
Fair Value Assumptions, Risk Free Interest Rate												1.22%
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life												7 years
Share Price					$ 0.1549						$ 0.187
Fair Value Assumptions, Weighted Average Volatility Rate											172.00%
Fair Value Assumptions, Risk Free Interest Rate		1.99%			1.99%						1.79%	2.20%
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period												4 years 11 days
Fair Value Assumptions, Expected Term					4 years 5 months 1 day
Fair Value Assumptions, Expected Volatility Rate		166.12%			166.00%
Maximum [Member] | Warrant [Member]
Summary Of Significant Accounting Policies [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights												$ 0.179
Share Price												$ 0.195
Fair Value Assumptions, Weighted Average Volatility Rate												178.00%
Fair Value Assumptions, Risk Free Interest Rate												1.87%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration Risk, Percentage												28.40%	45.30%
Major Customer Number One [Member] | Accounts Receivable [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration Risk, Percentage												18.00%	29.00%
Major Customer Number One [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration Risk, Percentage												18.00%	23.80%
Major Customer Number Two [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration Risk, Percentage												47.00%
Major Customer Number Two [Member] | Accounts Receivable [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration Risk, Percentage												14.00%	18.00%
Major Customer Number Two [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration Risk, Percentage												10.40%	21.50%
Major Customer Number Three [Member] | Accounts Receivable [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration Risk, Percentage												14.00%
Major Customer Number Four [Member] | Accounts Receivable [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration Risk, Percentage												13.00%
Major Customer Number Five [Member] | Accounts Receivable [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration Risk, Percentage												10.00%
Couponicate [Member]
Summary Of Significant Accounting Policies [Line Items]
Sale of Stock, Percentage of Ownership after Transaction														19.50%

MARKETABLE AND NON-MARKETABLE33

MARKETABLE AND NON-MARKETABLE SECURITIES (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2014
Marketable Securities, Current, Total	$ 750	$ 1,200
Marketable Securities, Unrealized Gain (Loss), Total	(450)	(2,400)
Investment Owned, at Cost			$ 50,000
Other than Temporary Impairment Losses, Investments	$ 0	$ 50,000
Ecologic Transportation [Member]
Number Of Shares Note Is Convertible Of Company			600,000
Investment Amount From Conversion Of Accounts Receivable			$ 60,000
Peartrack Security Systems Inc [Member]
Investment Owned, Balance, Shares	60,000	60,000
Investment Owned, at Fair Value		$ 24,000
Marketable Securities, Current, Total	$ 750	1,200
Loss On Conversion Of Accounts Receivable To Marketable Securities			$ 36,000
Marketable Securities, Unrealized Gain (Loss), Total	450	2,400
Cannonball Red [Member]
Investment Owned, Balance, Shares			97,500
Investment Owned, at Cost	97,500	2,016	$ 50,000
Repurchase Amount Of Cost Method Investment			$ 60,000
Other than Temporary Impairment Losses, Investments	$ 50,000	$ 0
Beta Music Group [Member]
Investment Owned, Balance, Shares		1,200,000	1,200,000
Investment Owned, at Cost			$ 0

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 66,645	$ 25,478
Less accumulated depreciation	(31,651)	(25,478)
Property and equipment, net	34,994	0
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	63,517	25,478
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 3,128	$ 0

PROPERTY AND EQUIPMENT (Detai35

PROPERTY AND EQUIPMENT (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Depreciation	$ 6,173	$ 0
Payments to Acquire Property, Plant, and Equipment	$ 41,167	$ 0
Property, Plant and Equipment, Estimated Useful Lives	3 years

INTANGIBLE ASSETS (Details)

INTANGIBLE ASSETS (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Intangible Assets
Accumulated amortization	$ (2,538,615)	$ (2,006,027)
Intangible assets, net	2,164,463	2,313,249
Patents
Intangible Assets
Finite-Lived Intangible Assets, Gross	3,697,709	3,697,710
Capitalized software development
Intangible Assets
Finite-Lived Intangible Assets, Gross	$ 1,005,369	$ 621,566

INTANGIBLE ASSETS (Details Text

INTANGIBLE ASSETS (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Software Development Costs
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 532,588	$ 570,247
Amortization of Intangible Assets	153,430	196,849
Finite-lived Intangible Assets Acquired	383,802	0
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	3,697,709	3,697,710
Amortization of Intangible Assets	379,158	373,398
Finite-lived Intangible Assets Acquired	$ 42,640	$ 0

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Textual) - USD ($)	1 Months Ended									12 Months Ended
	Nov. 30, 2017	Oct. 31, 2017	Jan. 31, 2017	Dec. 31, 2016	Nov. 30, 2016	Oct. 31, 2016	May 31, 2016	Apr. 30, 2016	Apr. 18, 2016	Dec. 31, 2017	Dec. 31, 2016	Oct. 11, 2017	May 02, 2017	Apr. 30, 2017	Dec. 31, 2015	Nov. 30, 2015	Oct. 09, 2015	Dec. 31, 2014
Cost method investment																		$ 50,000
Related party payables				$ 32,118						$ 23,535	$ 32,118
Debt Instrument, Face Amount																	$ 2,500,000
Debt Conversion, Converted Instrument, Shares Issued										11,346,726
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	8,125,000												1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.07		$ 0.25				$ 0.25	$ 0.001		$ 0.25						$ 0.10	$ 0.10
Stock Issued During Period, Shares, New Issues		10,714,286	357,143	41,666	41,666	41,666	11,714,285
Stock Issued During Period, Value, New Issues				$ 5,709	$ 4,917	$ 5,208
Due To Related Party For Unreimbursed Travel related Expenses				14,000						$ 14,000	14,000
Interest Payable, Current	$ 2,836
Other than Temporary Impairment Losses, Investments										$ 0	50,000
Class Of Warrant Or Right Term	5 years
Stock Issued During Period, Shares, Conversion of Convertible Securities	786,244							12,834,800		2,198,926
Stock Issued During Period, Value, Conversion of Convertible Securities								$ 1,025,000		$ 865,336	1,078,123
Proceeds from Issuance of Common Stock										1,550,000	2,129,082
Proceeds from Warrant Exercises	$ 157,500									$ 785,084
Stock Issued During Period, Shares, Exchange of Exercise of Warrants on Cashless Basis										18,225,681
Number of Warrants Excercised	750,000									18,353,310
Debt Instrument, Convertible, Conversion Price	$ 0.0672											$ 0.0672
Anthion Management LLC [Member]
Legal Fees											44,912
Convertible Notes Payable [Member]
Debt Instrument, Face Amount	$ 812,500
Debt Conversion, Converted Instrument, Shares Issued	1,530,292
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.10
Convertible Debt [Member]
Debt Instrument, Convertible, Conversion Price										$ 0.0672
Accounts Payable and Accrued Liabilities [Member]
Accrued Rent, Current				$ 0						$ 0	$ 0
Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				1,575,954						1,575,954	1,575,954
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.179	$ 0.25	$ 0.25			$ 0.25				$ 0.25			$ 0.10			$ 0.25
Proceeds from Warrant Exercises										$ 52,500
Minimum [Member]
Operating Leases, Rent Expense, Sublease Rentals										$ 500
Minimum [Member] | Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 0.038
Maximum [Member]
Operating Leases, Rent Expense, Sublease Rentals										$ 3,502
Maximum [Member] | Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 0.179
Executive Officer [Member]
Due to Related Parties				$ 20,575						$ 5,992	$ 20,575
Nathaniel Bradley
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				20,000							20,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.25							$ 0.25
Stock Issued During Period, Shares, New Issues											178,571
Stock Issued During Period, Value, New Issues											$ 25,000
Operating Leases, Rent Expense, Net, Total										16,371	$ 6,000
Director [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				180,000							180,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.25							$ 0.25
Stock Issued During Period, Shares, New Issues											1,607,137
Stock Issued During Period, Value, New Issues											$ 225,000
Peartrack Security Systems
Related party payables				$ 32,118						23,535	32,118
Shares owned																		60,000
Investment Owned, Balance, Shares																		60,000
Ecologic Transportation
Conversion of accounts receivable																		$ 60,000
Cannonball Red
Cost method investment				$ 0							$ 0							$ 50,000
Shares owned				97,500							97,500							97,500
Other than Temporary Impairment Losses, Investments											$ 50,000
Investment Owned, Balance, Shares				97,500							97,500							97,500
Sean Bradley
Due to Related Parties				$ 3,543						$ 3,543	$ 3,543
David Moradi
Due to Related Parties															$ 70,000
Interest Receivable															$ 4,280
Class Of Warrant Or Right Term										5 years
Stock Issued During Period, Shares, Conversion of Convertible Securities										11,346,726
Stock Issued During Period, Value, Conversion of Convertible Securities										$ 762,500
Stock Issued During Period, Shares, Exchange of Warrants Exercise										750,000
Proceeds from Warrant Exercises										$ 52,500
David Moradi | Convertible Debt [Member]
Debt Instrument, Face Amount										$ 762,500
David Moradi | Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										7,625,000
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 0.07
KTK Capital Inc [Member] | Convertible Notes Payable [Member]
Debt Conversion, Original Debt, Amount									$ 200,000
Debt Conversion, Converted Instrument, Shares Issued									2,506,849
Interest Payable, Current									$ 10,575
FBO Alexandre Zynier IRA [Member] | Convertible Notes Payable [Member]
Debt Conversion, Original Debt, Amount									$ 100,000
Debt Conversion, Converted Instrument, Shares Issued									1,251,142
Interest Payable, Current									$ 5,096
Anthion Partners and Anthion Partners II LLC [Member] | Convertible Notes Payable [Member]
Debt Conversion, Original Debt, Amount									$ 1,475,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									18,353,310
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 0.175
Interest Payable, Current									$ 66,678
CSB IV Holdings [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				292,000							292,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.25							$ 0.25
Stock Issued During Period, Shares, New Issues											2,607,143
Stock Issued During Period, Value, New Issues											$ 365,000
Anthon Capital Management [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				100,000							100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.25							$ 0.25
Stock Issued During Period, Shares, New Issues											892,857
Stock Issued During Period, Value, New Issues											$ 125,000
Anthon Partners II, LLC [Member]
Stock Issued During Period, Shares, New Issues										5,357,143
Proceeds from Issuance of Common Stock										$ 750,000

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Notes and loans payable
Short Term	$ 0	$ 23,800
Maryland TEDCO Note
Notes and loans payable
Short Term	$ 0	$ 23,800

NOTES PAYABLE (Details Textual)

NOTES PAYABLE (Details Textual) - USD ($)	Oct. 11, 2017	May 02, 2017	Apr. 11, 2017	Nov. 30, 2017	Apr. 30, 2016	Oct. 24, 2011	Nov. 30, 2015	Dec. 31, 2017	Dec. 31, 2016	Jan. 31, 2017	May 31, 2016	Oct. 09, 2015	Dec. 31, 2012
Debt Instrument [Line Items]
Interest Payable, Current				$ 2,836
Debt Instrument, Face Amount												$ 2,500,000
Notes and Loans Payable, Current, Total								$ 0	$ 23,800
Debt Instrument, Convertible, Number of Equity Instruments				12,090,774
Interest Expense, Debt			$ 39,944	$ 812,500
Debt Instrument, Convertible, Conversion Price	$ 0.0672			$ 0.0672
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,000,000		8,125,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.07	$ 0.001		$ 0.10	$ 0.25		$ 0.25	$ 0.25	$ 0.10
Fair Value Assumptions, Expected Term	5 years	3 years 4 months 24 days		5 years
Fair Value Assumptions, Expected Dividend Rate	0.00%			0.00%
Fair Value Assumptions, Risk Free Interest Rate		1.45%
Shares Issued, Price Per Share				$ 0.07
Amortization of Debt Discount (Premium)								$ 862,500	600,301
Gain (Loss) on Extinguishment of Debt				$ 15,724				(15,724)	(1,664,281)
Warrants Not Settleable in Cash, Fair Value Disclosure			89,944
Proceeds from Convertible Debt			$ 50,000					$ 862,500	0
Stock Issued During Period, Shares, Conversion of Convertible Securities				786,244	12,834,800			2,198,926
Proceeds from Warrant Exercises				$ 157,500				$ 785,084
Class Of Warrants Or Right Exercisable Term	warrants exercisable for shares of Common Stock at a price of $0.07 per share if exercised during the Discount Period or $0.10 per share if exercised during the term of the warrant following the Discount Period; (ii) provide for certain registration rights for shares of Common Stock issued pursuant to the Original Purchase Agreement, as amended, at any time after 30 days subsequent to the listing of the Common Stock on a national securities exchange; and (iii) amend the Warrants such that they are exercisable for shares of Common Stock at a price of $0.07 per share if exercised during the Discount Period or $0.10 per share if exercised during the term of the warrant following the Discount Period. The Company recognized a charge of $13,262 to current period interest for change in fair value due to the warrant modifications using the Black-Scholes pricing model
Class Of Warrant Or Right Term				5 years
Number of Warrants Excercised				750,000				18,353,310
Warrant [Member]
Debt Instrument [Line Items]
Debt Conversion Total Issued And Outstanding Common Shares Percent			60.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.10
Proceeds from Sale of Available-for-sale Securities, Equity			$ 1,000,000
Warrants Term			5 years
Maximum [Member]
Debt Instrument [Line Items]
Fair Value Assumptions, Expected Term				4 years 5 months 1 day
Fair Value Assumptions, Expected Volatility Rate	166.12%			166.00%
Fair Value Assumptions, Risk Free Interest Rate	1.99%			1.99%			1.79%	2.20%
Minimum [Member]
Debt Instrument [Line Items]
Fair Value Assumptions, Expected Term				2 years 11 months 8 days
Fair Value Assumptions, Expected Volatility Rate	165.18%			165.00%
Fair Value Assumptions, Risk Free Interest Rate	1.60%			1.60%			1.14%	1.98%
Note and Warrant Purchase Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			10.00%
Debt Instrument, Face Amount			$ 50,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			500,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage			50.00%
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount				$ 812,500
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.10
Loans Payable
Debt Instrument [Line Items]
Long-term Debt, Gross													$ 74,900
Debt Instrument, Interest Rate, Stated Percentage													25.00%
Interest Payable, Current													$ 74,900
Maryland TEDCO Note
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Total						$ 2,000
Debt Instrument, Face Amount						$ 149,800
Notes and Loans Payable, Current, Total								$ 0	$ 23,800

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details)	Dec. 31, 2017USD ($)
2,018	$ 177,450
2,019	168,503
2,020	119,629
2,021	91,466
Total	$ 557,048

COMMITMENTS AND CONTINGENCIES42

COMMITMENTS AND CONTINGENCIES (Details Textual)

Feb. 01, 2018USD ($)a

Feb. 01, 2018USD ($)a

Aug. 10, 2017USD ($)shares

Dec. 07, 2016USD ($)$ / sharesshares

Nov. 10, 2015USD ($)shares

Oct. 01, 2015USD ($)

Jul. 03, 2015USD ($)

Jul. 01, 2015

May 01, 2015USD ($)

Aug. 07, 2013USD ($)

Dec. 31, 2017USD ($)a$ / shares

Dec. 21, 2017USD ($)

Sep. 30, 2017USD ($)

Jun. 22, 2017shares

Feb. 23, 2017shares

Sep. 02, 2016USD ($)

Jul. 25, 2016USD ($)

Mar. 31, 2016USD ($)

Dec. 22, 2015shares

Apr. 24, 2015shares

Mar. 31, 2015USD ($)

Mar. 31, 2014USD ($)

Jun. 30, 2017USD ($)

Mar. 31, 2017USD ($)

Dec. 31, 2017USD ($)a$ / sharesshares

Dec. 31, 2016USD ($)shares

Dec. 31, 2014shares

Nov. 30, 2017$ / shares

May 02, 2017$ / shares

Nov. 30, 2015$ / shares

Commitments And Contingencies [Line Items]

Area Of Principal Executive Offices | a

2,362

2,362

Operating Leases, Rent Expense

$ 144,030

$ 109,340

Lease Rent Per Month

$ 3,937

$ 5,474

$ 4,724

6,224

Litigation Settlement, Amount Awarded from Other Party

$ 1,525,000

Payments for Legal Settlements

$ 100,000

Deferred Rent Credit

$ 14,450

$ 14,450

Accrued Rent

$ 14,657

Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares

250,000

Share Price | $ / shares

$ 0.1549

$ 0.1549

$ 0.20

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares

2,655,851

0

Lessee, Operating Lease, Term of Contract

2021 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value

$ 268,300

Lease Rent,Month to Month Basis

$ 300

Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost

268,300

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Description

The settlement date for such RSUs, as amended, in the earlier of (i) July 1, 2024 or (ii) the date on which the Company undergoes a change of control. The change in vesting terms were considered a modification of equity based instrument and accordingly charged the change in estimated fair value of $41,250 to current period operations.

PSUs [Member]

Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value

737,825

Restricted Stock Units (RSUs) [Member]

Commitments And Contingencies [Line Items]

Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares

263,554

263,554

402,297

250,000

Stock Issued During Period, Value, Restricted Stock Award, Gross

$ 43,486

$ 66,379

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares

1,325,000

250,000

150,000

1,252,620

Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost

$ 41,250

26,515

Sublease in Atlanta [Member]

Commitments And Contingencies [Line Items]

Lease Rent Per Month

$ 2,763

Area of Land | a

3,831

3,831

Sublease in Scottsdale, AZ [Member]

Commitments And Contingencies [Line Items]

Operating Leases, Rent Expense, Sublease Rentals

3,502

Maximum [Member]

Commitments And Contingencies [Line Items]

Operating Leases, Rent Expense, Sublease Rentals

3,502

Share Price | $ / shares

$ 0.1549

$ 0.187

Minimum [Member]

Commitments And Contingencies [Line Items]

Operating Leases, Rent Expense, Sublease Rentals

500

Share Price | $ / shares

$ 0.139

$ 0.031

Subsequent Event [Member]

Commitments And Contingencies [Line Items]

Lease Rent Per Month

$ 9,598

$ 1,500

Lease Rent Per Month To Be Escalated At Lease Term

$ 10,185

$ 10,185

Area of Land | a

4,248

4,248

Nathaniel Bradley

Commitments And Contingencies [Line Items]

Officers' Compensation

$ 175,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period | shares

2,000,000

Sean Bradley

Commitments And Contingencies [Line Items]

Base Salary

$ 200,000

Officers' Compensation

$ 150,000

Share Price Condition

(a) satisfaction of a share price condition described below; and (b) 100% achievement of the performance goals by the company and Mr. Bradley, as applicable. Subject to the share price condition, 50% of the target award will be earned by Mr. Bradley at the 85% achievement level, and he can earn up to 150% of the target award at the 125% achievement level. Vesting shall be determined based upon performance measures at the end of each calendar year of 2016 and 2017, with 50% of each target award and performance increase subject to vesting during each performance period.

Performance Objective Description

(a) Targeted cash contract bookings (as to 33.33%); (b) Targeted net operating cash flow (as to 33.33%); (c) Board defined operations goals (as to 33.33%) for a performance period. And, vesting shall only occur if the closing share price of the companys common stock on each of the 20 trading days before and including the end of a performance period is not less than $0.20 per share (as adjusted for stock splits, combinations, recapitalization and the like).

Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost

$ 201,225

President [Member]

Commitments And Contingencies [Line Items]

Stock Granted, Value, Share-based Compensation, Gross

$ 6,250

Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period | shares

1,500,000

Dr. Carr Bettis [Member]

Commitments And Contingencies [Line Items]

Officers' Compensation

$ 175,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period | shares

2,000,000

Share Price Condition

(a) satisfaction of a share price condition described below; and (b) 100% achievement of the performance goals by the company and Dr. Bettis, as applicable. Subject to the share price condition, 50% of the target award will be earned by Dr. Bettis at the 85% achievement level, and he can earn up to 150% of the target award at the 125% achievement level. Vesting shall be determined based upon performance measures at the end of each calendar year of 2016 and 2017, with 50% of each target award and performance increase subject to vesting during each performance period.

Performance Objective Description

(a) Targeted cash contract bookings (as to 33.33%); (b) Targeted net operating cash flow (as to 33.33%); (c) Board defined operations goals (as to 33.33%) for a performance period. And, vesting shall only occur if the closing share price of the companys common stock on each of the 20 trading days before and including the end of a performance period is not less than $0.20 per share (as adjusted for stock splits, combinations, recapitalization and the like).

Dr. Carr Bettis [Member] | Restricted Stock Units (RSUs) [Member]

Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares

665,000

Todd Bankofier [Member]

Commitments And Contingencies [Line Items]

Base Salary

$ 250,000

Share Price Condition

(a) satisfaction of a share price condition described below; and (b) 100% achievement of the performance goals by the company and Mr. Bankofier, as applicable. Subject to the share price condition, 50% of the target award will be earned by Mr. Bankofier at the 85% achievement level, and he can earn up to 150% of the target award at the 125% achievement level. Vesting shall be determined based upon performance measures at the end of each calendar year of 2016 and 2017, with 50% of each target award and performance increase subject to vesting during each performance period.

Performance Objective Description

(a) Targeted cash contract bookings (as to 33.33%); (b) Targeted net operating cash flow (as to 33.33%); (c) Board defined operations goals (as to 33.33%) for a performance period. And, vesting shall only occur if the closing share price of the companys common stock on each of the 20 trading days before and including the end of a performance period is not less than $0.20 per share (as adjusted for stock splits, combinations, recapitalization and the like).

Director [Member]

Commitments And Contingencies [Line Items]

Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares

602,620

Stock Issued During Period, Value, Restricted Stock Award, Gross

$ 72,917

Share Price | $ / shares

$ 0.121

Director [Member] | Restricted Stock Units (RSUs) [Member]

Commitments And Contingencies [Line Items]

Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares

650,000

Chief Technology Officer [Member] | PSUs [Member]

Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares

93,750

Chief Technology Officer [Member] | Performance Target [Member] | PSUs [Member]

Commitments And Contingencies [Line Items]

Percentage Performance Targets Met

125.00%

Chief Technology Officer [Member] | Revenue goal | PSUs [Member]

Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted | shares

200,000

Percentage Psus Awards Granted

37.50%

Targeted Revenue Goals upon Awards Granted

$ 22,000,000

$ 8,000,000

$ 1,700,000

Chief Technology Officer [Member] | Discretionary Goal | PSUs [Member]

Commitments And Contingencies [Line Items]

Percentage Psus Awards Granted

75.00%

Chief Technology Officer [Member] | Project Plan Deliverable Schedule and Related Project Budget [Member] | PSUs [Member]

Commitments And Contingencies [Line Items]

Percentage Psus Awards Granted

25.00%

Chief Technology Officer [Member] | Maximum [Member] | Performance Target [Member] | PSUs [Member]

Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted | shares

300,000

Chief Technology Officer [Member] | Minimum [Member] | Performance Target [Member] | PSUs [Member]

Commitments And Contingencies [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted | shares

100,000

STOCKHOLDERS_ EQUITY (Details)

STOCKHOLDERS’ EQUITY (Details) - USD ($)	Jul. 10, 2017	Dec. 02, 2016	Jan. 15, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding
Outstanding at beginning of the period (in shares)				25,731,207
Granted (in shares)	1,250,000	1,391,188	6,500,000
Outstanding at the end of the period (in shares)				25,095,557	25,731,207
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Granted (in dollars per share)		$ 0.121	$ 0.038
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding
Outstanding at beginning of the period (in shares)			14,759,914	25,731,207	14,759,914
Granted (in shares)				1,450,000	12,508,877
Forfeited/Expired (in shares)				(2,085,650)	(1,537,584)
Outstanding at the end of the period (in shares)				25,095,557	25,731,207	14,759,914
Exercisable (in shares)				22,276,224	15,091,366	8,374,294
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Outstanding at beginning of the period (in dollars per share)			$ 0.30	$ 0.20	$ 0.30
Granted (in dollars per share)				0.16	0.09
Forfeited/Expired (in dollars per share)				0.34	0.29
Outstanding at end of the period (in dollars per share)				$ 0.19	$ 0.20	$ 0.30
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures
Outstanding, Weighted Average Remaining Term				2 years 7 months 20 days	3 years 4 months 2 days	3 years 7 months 10 days
Granted Weighted Average Remaining Term				5 years	4 years 10 months 13 days
Share Based Compensation Arrangement by Share Based Payment Award Options, Intrinsic Value
Outstanding, Intrinsic Value (in dollars)				$ 1,356,188	$ 1,161,244	$ 235,330
Granted, Intrinsic Value of Exercisable Options				$ 0	$ 0
Forfeited, Intrinsic Value of Exercisable Options				$ 0

STOCKHOLDERS_ EQUITY (Details 1

STOCKHOLDERS’ EQUITY (Details 1) - USD ($)	1 Months Ended	12 Months Ended
	Oct. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Number of warrants
Number of shares, granted		2,655,851	0
Warrant
Number of warrants
Number of shares, beginning		63,433,041	43,246,858
Number of shares, granted		9,165,000	21,681,264
Number of shares, exercised		(24,353,310)
Number of shares, Forfeited		(247,396)	(1,495,081)
Number of shares, ending		47,997,335	63,433,041	43,246,858
Weighted average exercise price
Weighted average exercise price, beginning (in dollars per share)		$ 0.15	$ 0.22
Weighted average exercise price, granted (in dollars per share) | $ / shares	$ 33,785	0.1	0.03
Weighted average exercise price, exercised (in dollars per share)		0.03
Weighted average exercise price, Forfeited (in dollars per share)		0.49	0.48
Weighted average exercise price, ending (in dollars per share)		$ 0.20	$ 0.15	$ 0.22
Weighted Average Remaining Term
Wtd Avg. Remaining Term		2 years 7 months 10 days	3 years 6 months 18 days	4 years 1 month 24 days
Weighted Average Remaining Term		4 years 10 months 20 days	4 years 10 months 13 days
Intrinsic Value
Outstanding, Intrinsic Value		$ 1,656,083	$ 3,662,610	$ 1,167

STOCKHOLDERS_ EQUITY (Details 2

STOCKHOLDERS’ EQUITY (Details 2) - shares	Aug. 10, 2017	Dec. 07, 2016	Apr. 24, 2015	Dec. 31, 2017	Dec. 31, 2016
Granted				2,655,851	0
Restricted Stock Units (RSUs) [Member]
Granted	1,325,000	250,000	150,000		1,252,620
Number of shares, ending				3,908,471	1,252,620
Vested at December 31, 2017				1,918,471
Unvested restricted shares as of December 31, 2017				1,990,000

STOCKHOLDERS' EQUITY (Details T

STOCKHOLDERS' EQUITY (Details Textual) - USD ($)	Jan. 01, 2018	Oct. 11, 2017	Aug. 10, 2017	Jul. 10, 2017	May 02, 2017	Mar. 10, 2017	Dec. 07, 2016	Dec. 02, 2016	Oct. 15, 2016	Jul. 15, 2016	May 12, 2016	Jan. 15, 2016	Jan. 04, 2016	Oct. 09, 2015	May 01, 2015	Dec. 31, 2017	Nov. 30, 2017	Oct. 31, 2017	Jun. 22, 2017	May 31, 2017	Apr. 30, 2017	Mar. 31, 2017	Feb. 28, 2017	Feb. 23, 2017	Jan. 31, 2017	Jan. 17, 2017	Dec. 31, 2016	Nov. 30, 2016	Oct. 31, 2016	Sep. 30, 2016	Aug. 31, 2016	Jul. 31, 2016	Jun. 15, 2016	May 31, 2016	Apr. 30, 2016	Apr. 15, 2016	Apr. 24, 2015	Nov. 30, 2015	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Class of Stock [Line Items]
Common Stock, Shares, Issued																161,664,077											111,512,001														161,664,077	111,512,001
Common Stock, Shares, Outstanding																161,664,077											111,512,001														161,664,077	111,512,001
Granted (in shares)				1,250,000				1,391,188				6,500,000
Proceeds from Issuance of Warrants																																		$ 1,579,082							$ 210,000	$ 0
Stock Issued During Period, Shares, Issued for Services																				528,302	41,674	41,666	41,666		41,666					41,666	41,666	124,998			83,336
Stock Issued During Period Value Warrants Exercised														1,792,000				1,500,000																1,312,000
Debt Conversion, Converted Instrument, Shares Issued																																									11,346,726
Stock Issued During Period, Value, Issued for Services																					$ 7,126	$ 5,917	$ 5,333		$ 6,625					$ 6,292	$ 6,208	$ 20,666			$ 14,292						$ 25,001	$ 63,292
Stock Issued During Period, Shares, New Issues																		10,714,286							357,143		41,666	41,666	41,666					11,714,285
Stock Issued During Period, Value, New Issues																											$ 5,709	$ 4,917	$ 5,208
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					1,000,000												8,125,000
Class of Warrant or Right, Exercise Price of Warrants or Rights														$ 0.10		$ 0.25	$ 0.07								$ 0.25									$ 0.25	$ 0.001			$ 0.10			$ 0.25
Fair Value Assumptions, Risk Free Interest Rate					1.45%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				1,250,000				1,391,188				6,500,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price								$ 0.121				$ 0.038
Stock Issued During Period, Shares, Restricted Stock Award, Gross																																										250,000
Share Price					$ 0.20											0.1549																									$ 0.1549
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period														5 years																								5 years			5 years
Proceeds from Issuance of Private Placement																									$ 50,000
Class of Warrant or Right, Outstanding																	2,000,000										18,353,310								18,353,310							18,353,310
Preferred Stock, Par or Stated Value Per Share																$ 0.00001											$ 0.00001														$ 0.00001	$ 0.00001
Stock Issued During Period, Shares, Conversion of Convertible Securities																	786,244																		12,834,800						2,198,926
Stock Issued During Period, Value, Conversion of Convertible Securities																																			$ 1,025,000						$ 865,336	$ 1,078,123
Interest Payable																																			53,123
Payments of Stock Issuance Costs																																		$ 63,292
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance																25,095,557											25,731,207														25,095,557	25,731,207
Share Based Compensation Arrangement by Share Based Payment Award, Options, Grants in Period Grant Date Fair Value								$ 150,875								$ 150,500																									$ 150,500
Allocated Share-based Compensation Expense																																									102,083
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights				1,000,000 options vested immediately and 250,000 options vest 50% after approximately nine months, with an additional 4.17% vesting every month thereafter								Vesting shall only occur if the closing share price of the Companys common stock on each of the 20 trading days before and including the end of any performance period is not less than $0.20 per share (market condition)
Accrued Salaries, Current																$ 14,583											$ 72,917														$ 14,583	$ 72,917
Fair Value Assumptions, Weighted Average Volatility Rate					171.00%																																				163.90%
Stock Issued During Period Shares Warrants Exercised																	2,250,000								40,000																750,000
Stock Issued During Period, Shares, Common Stock in Exchange for Warrants																18,225,681
Warrant Exercise Shares Issued																18,353,310				1,000,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price				$ 0.166
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value																																									$ 268,300
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost																																									7,782
Salaries, Wages and Officers' Compensation																																									87,500
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost																																									$ 268,300
Common Stock, Par or Stated Value Per Share																$ 0.00001		$ 0.14									$ 0.00001														$ 0.00001	$ 0.00001
Proceeds from Warrant Exercises																	$ 157,500																								$ 785,084
Debt Conversion, Converted Instrument, Amount																																									$ 865,336	$ 1,078,123
Stock issued during period, shares, for Exchange of exercise of warrants on cahsless basis																	1,078,947
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period																																									2,655,851	0
Restricted Stock or Unit Expense																																									$ 418,832	$ 0
Current Year Restricted Stock Expenses																																									404,249
Prior Year Restricted Stock Expenses																																									14,583
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options																$ 178,115																									178,115
Convertible Notes Payable [Member]
Class of Stock [Line Items]
Debt Conversion, Converted Instrument, Shares Issued																	1,530,292
Class of Warrant or Right, Exercise Price of Warrants or Rights																	$ 0.10
Class of Warrant or Right, Outstanding																											1,664,281															1,664,281
Debt Instrument, Convertible, If-converted Value in Excess of Principal																																			$ 1,541,678							$ 1,541,678
Warrants and Rights Outstanding																											$ 3,205,959															3,205,959
Warrants issued during period																	8,125,000
Debt Conversion, Converted Instrument, Amount																	$ 102,836																								$ 762,500
Share-based Compensation Award, Tranche One [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage								50.00%
Share-based Compensation Award, Tranche Two [Member]
Class of Stock [Line Items]
Granted (in shares)	327,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	327,500
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage								25.00%
Share-based Compensation Award, Tranche Three [Member]
Class of Stock [Line Items]
Granted (in shares)	250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	250,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage								25.00%
Employee Stock Option [Member]
Class of Stock [Line Items]
Expected dividend yield (as a percent)																																									0.00%
Allocated Share-based Compensation Expense																																									$ 1,236,863	$ 864,024
Deferred Compensation Liability, Current and Noncurrent																$ 111,996																									$ 111,996
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																																									0.00%
Blackscholes Option Pricing Model [Member]
Class of Stock [Line Items]
Fair Value Assumptions, Risk Free Interest Rate																																										1.24%
Share Price																											$ 0.175															$ 0.175
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																																										5 years
Fair Value Assumptions, Weighted Average Volatility Rate																																										178.00%
Accredited investors [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues																											3,928,573
Class of Warrant or Right, Exercise Price of Warrants or Rights																									$ 0.12
Class Of Warrant Or Right Grant Date Fair Value																									$ 29,433
Warrants to Purchase Common Stock Shares																																									250,000
Warrant [Member]
Class of Stock [Line Items]
Stock Issued During Period Value Warrants Exercised																					500,000				40,000		440,000							1,312,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																1,575,954											1,575,954														1,575,954	1,575,954
Class of Warrant or Right, Exercise Price of Warrants or Rights														$ 0.25				$ 0.179			$ 0.10				$ 0.25		$ 0.25							$ 0.25								$ 0.25
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period														5 years
Expected term																																									3 years
Expected volatility (as a percent)																																									175.64%
Risk-free interest rate (as a percent)																																									1.48%
Expected dividend yield (as a percent)																																									0.00%	0.00%
Allocated Share-based Compensation Expense																																									$ 109,509	$ 221,621
Deferred Compensation Liability, Current and Noncurrent																$ 1,393																									$ 1,393
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum																																										166.74%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum																																										178.98%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum																																										0.71%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum																																										1.08%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																																									0.00%	0.00%
Class Of Warrant Or Right Issued																																										1,492,620
Warrants Issued during period, Issued for Services																		250,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value																		$ 33,785																							$ 0.1	$ 0.03
Proceeds from Warrant Exercises																																									$ 52,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period																																									9,165,000	21,681,264
Restricted Stock
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value			$ 107,250
Performance Options [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage																																									100.00%
Expected term												5 years
Expected volatility (as a percent)												162.00%
Risk-free interest rate (as a percent)												1.46%
Expected dividend yield (as a percent)												0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate												0.00%
Performance Options [Member] | Performance and Market Conditions [Member]
Class of Stock [Line Items]
Granted (in shares)												5,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross												5,500,000
Non Performance Options [Member]
Class of Stock [Line Items]
Expected dividend yield (as a percent)																																										0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																																										0.00%
Options Granted On April 2016 [Member]
Class of Stock [Line Items]
Granted (in shares)																																				49,715
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																																				49,715
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price																																				$ 0.179
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date																																				Apr. 15, 2019
Share Based Compensation Arrangement by Share Based Payment Award, Options, Grants in Period Grant Date Fair Value																																				$ 6,250
Options Granted On May 2016 One [Member]
Class of Stock [Line Items]
Granted (in shares)											100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 0.177
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross											100,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date											May 12, 2021
Share Based Compensation Arrangement by Share Based Payment Award, Options, Grants in Period Grant Date Fair Value											$ 16,694
Options Granted On May 2016 One [Member] | Share-based Compensation Award, Tranche One [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage											50.00%
Options Granted On May 2016 One [Member] | Share-based Compensation Award, Tranche Two [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage											4.17%
Options Granted On May 2016 Two [Member]
Class of Stock [Line Items]
Granted (in shares)											3,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross											3,400,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price											$ 0.177
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date											May 12, 2021
Share Based Compensation Arrangement by Share Based Payment Award, Options, Grants in Period Grant Date Fair Value											$ 559,603
Options Granted On May 2016 Two [Member] | Share-based Compensation Award, Tranche One [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage											50.00%
Options Granted On May 2016 Two [Member] | Share-based Compensation Award, Tranche Two [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage											50.00%
Options Granted On July 2016 [Member]
Class of Stock [Line Items]
Granted (in shares)										56,375
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										56,375
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price										$ 0.156
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date										Jul. 15, 2019
Share Based Compensation Arrangement by Share Based Payment Award, Options, Grants in Period Grant Date Fair Value										$ 6,250
Options Granted On June 2016 [Member]
Class of Stock [Line Items]
Granted (in shares)																																	300,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																																	300,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date																																	Jun. 15, 2021
Share Based Compensation Arrangement by Share Based Payment Award, Options, Grants in Period Grant Date Fair Value																																	$ 40,723
Options Granted On June 2016 [Member] | Share-based Compensation Award, Tranche One [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage																																	50.00%
Options Granted On October 2016 [Member]
Class of Stock [Line Items]
Granted (in shares)									61,599
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									61,599
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price									$ 0.121
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date									Oct. 15, 2019
Share Based Compensation Arrangement by Share Based Payment Award, Options, Grants in Period Grant Date Fair Value									$ 5,209
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Restricted Stock Award, Gross																																							$ 43,486	$ 66,379
Stock Issued During Period, Shares, Restricted Stock Award, Gross			263,554																263,554					402,297																		250,000
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost			$ 41,250																																						$ 26,515
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number			650,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			1,325,000				250,000																														150,000					1,252,620
Options Granted On January 2017 [Member]
Class of Stock [Line Items]
Granted (in shares)																										100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights																										$ 0.159
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																										100,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date																										Jan. 17, 2022
Share Based Compensation Arrangement by Share Based Payment Award, Options, Grants in Period Grant Date Fair Value																										$ 11,119
Options Granted On January 2017 [Member] | Share-based Compensation Award, Tranche One [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage																										50.00%
Options Granted On January 2017 [Member] | Share-based Compensation Award, Tranche Two [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage																										2.08%
Options Granted On March 2017 [Member]
Class of Stock [Line Items]
Granted (in shares)						100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.145
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						100,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date						Mar. 10, 2022
Share Based Compensation Arrangement by Share Based Payment Award, Options, Grants in Period Grant Date Fair Value						$ 12,541
Options Granted On March 2017 [Member] | Share-based Compensation Award, Tranche One [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						50.00%
Options Granted On March 2017 [Member] | Share-based Compensation Award, Tranche Two [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						2.08%
Performance Shares [Member]
Class of Stock [Line Items]
Expected term																																									1 year 6 months 7 days
Expected volatility (as a percent)																																									163.87%
Risk-free interest rate (as a percent)																																									1.76%
Expected dividend yield (as a percent)																																									0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate																																									0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares																																									5,500,000
Reversal of Share Based Compensation Expense																																									$ 58,830
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value																																									$ 737,825
Maximum
Class of Stock [Line Items]
Fair Value Assumptions, Risk Free Interest Rate		1.99%															1.99%																					1.79%			2.20%
Share Price																	$ 0.1549																					$ 0.187
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																																									4 years 11 days
Fair Value Assumptions, Weighted Average Volatility Rate																																						172.00%
Maximum | Employee Stock Option [Member]
Class of Stock [Line Items]
Expected term																																									3 years 6 months
Expected volatility (as a percent)																																									175.56%
Risk-free interest rate (as a percent)																																									1.66%
Maximum | Warrant [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights																$ 0.179																									$ 0.179
Fair Value Assumptions, Risk Free Interest Rate																																									1.87%
Share Price																0.195																									$ 0.195
Expected term																																										2 years 6 months
Fair Value Assumptions, Weighted Average Volatility Rate																																									178.00%
Maximum | Non Performance Options [Member]
Class of Stock [Line Items]
Expected term																																										3 years 6 months
Expected volatility (as a percent)																																										176.77%
Risk-free interest rate (as a percent)																																										1.73%
Minimum
Class of Stock [Line Items]
Fair Value Assumptions, Risk Free Interest Rate		1.60%															1.60%																					1.14%			1.98%
Share Price																	$ 0.139																					$ 0.031
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																																									2 years 9 months 7 days
Fair Value Assumptions, Weighted Average Volatility Rate																																						102.00%
Minimum | Employee Stock Option [Member]
Class of Stock [Line Items]
Expected term																																									2 years 6 months
Expected volatility (as a percent)																																									169.46%
Risk-free interest rate (as a percent)																																									1.42%
Minimum | Warrant [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights																0.038																									$ 0.038
Fair Value Assumptions, Risk Free Interest Rate																																									1.22%
Share Price																$ 0.152																									$ 0.152
Expected term																																										1 year 6 months
Fair Value Assumptions, Weighted Average Volatility Rate																																									169.00%
Minimum | Non Performance Options [Member]
Class of Stock [Line Items]
Expected term																																										1 year 6 months
Expected volatility (as a percent)																																										102.00%
Risk-free interest rate (as a percent)																																										0.87%
Accredited investors
Class of Stock [Line Items]
Proceeds from Issuance of Warrants																											$ 550,000
Stock Issued During Period Value Warrants Exercised																											440,000
Class of Warrant or Right, Exercise Price of Warrants or Rights																											$ 0.25															$ 0.25
Board of Directors Chairman [Member] | Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value																			$ 665,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period																			665,000
Board of Directors Chairman [Member] | Restricted Stock Units (RSUs) [Member] | Ernest Purcell [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 40,000
Board of Directors Chairman [Member] | Restricted Stock Units (RSUs) [Member] | Alexandre Zyngier [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value			40,000
Officer [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price													$ 0.038
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date													Jan. 4, 2019
Officer [Member] | Maximum
Class of Stock [Line Items]
Granted (in shares)													500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross													500,000
Officer [Member] | Minimum
Class of Stock [Line Items]
Granted (in shares)													150,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross													150,000
Director [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Restricted Stock Award, Gross							$ 72,917
Stock Issued During Period, Shares, New Issues																																										1,607,137
Stock Issued During Period, Value, New Issues																																										$ 225,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																											180,000															180,000
Class of Warrant or Right, Exercise Price of Warrants or Rights																											$ 0.25															$ 0.25
Stock Issued During Period, Shares, Restricted Stock Award, Gross							602,620
Share Price							$ 0.121
Director [Member] | Ernest Purcell [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value			415,000
Director [Member] | Alexandre Zyngier [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value			415,000
Director [Member] | Anthony Coelho [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 415,000
Director [Member] | Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross							650,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized							$ 87,750
Management [Member]
Class of Stock [Line Items]
Granted (in shares)				1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				1,000,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Common Stock, Shares, Issued																110,000											160,000														110,000	160,000
Redemption Price (in dollars per share)																$ 0.1754																									$ 0.1754
Preferred Stock, Dividend Rate, Percentage															5.00%
Preferred Stock, Par or Stated Value Per Share																$ 10											$ 10														$ 10	$ 10
Stock Issued During Period Shares Conversion Of Preferred Stock																		3,204,027																900,525
Conversion of Stock, Shares Converted																		50,000																15,000
Dividends, Preferred Stock, Stock																																									$ 75,206	$ 80,000
Common Stock Dividends, Shares																																									428,783	442,372
Dividends Payable																$ 146,918											$ 133,699														$ 146,918	$ 133,699
Preferred stock unpaid dividend equivalent common stock, Shares																																									837,617	762,252

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Net operating loss carry forwards	$ 5,014,461	$ 7,558,530
Less valuation allowance	(5,014,461)	(7,558,530)
Net deferred tax asset	$ 0	$ 0

INCOME TAXES (Details Textual)

INCOME TAXES (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Operating Loss Carryforwards		$ 23,878,387	$ 22,716,669
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		35.00%
Scenario, Plan [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%

SUBSEQUENT EVENTS (Details Text

SUBSEQUENT EVENTS (Details Textual) - $ / shares	Dec. 01, 2018	Mar. 09, 2018	Jan. 01, 2018	Aug. 10, 2017	Jul. 10, 2017	Dec. 07, 2016	Dec. 02, 2016	Jan. 15, 2016	Apr. 24, 2015	Dec. 31, 2017	Dec. 31, 2016
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					1,250,000		1,391,188	6,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period										2,655,851	0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price							$ 0.121	$ 0.038
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights					1,000,000 options vested immediately and 250,000 options vest 50% after approximately nine months, with an additional 4.17% vesting every month thereafter			Vesting shall only occur if the closing share price of the Companys common stock on each of the 20 trading days before and including the end of any performance period is not less than $0.20 per share (market condition)
Share-based Compensation Award, Tranche Two [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			327,500
Share-based Compensation Award, Tranche Three [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			250,000
Restricted Stock Units (RSUs) [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				1,325,000		250,000			150,000		1,252,620
Subsequent Event
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		1,537,339
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	The options are exercisable at $0.258 for five years with (i) 959,839 options vesting 50% at the first day of each month beginning January 1, 2018 through December 1, 2018, 25% vesting at the first day of each month from January 1, 2019 through December 1, 2019 and 25% vesting at the first day of each month beginning January 1, 2020 through December 1, 2020; (ii) 327,500 options vesting 50% on January 1, 2018, 50% vesting at each month beginning on January 1, 2019 for 24 months; and (iii) 250,000 options fully vesting on January 1, 2018.
Subsequent Event | Share-based Compensation Award, Tranche One [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	959,839